# EDGAR Filing Document

**Accession Number:** 0001813914
**File Stem:** 0000950170-23-010647
**Filing Date:** 2023-3
**Character Count:** 187271
**Document Hash:** 922311d49a07ec5dba3f4b402572a9b9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-010647.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0000950170-23-010647

**CONFORMED SUBMISSION TYPE**: 10-Q/A

**PUBLIC DOCUMENT COUNT**: 80

**CONFORMED PERIOD OF REPORT**: 20220930

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CareMax, Inc.
- **CENTRAL INDEX KEY:** 0001813914
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-NURSING & PERSONAL CARE FACILITIES [8050]
- **IRS NUMBER:** 850992224
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39391
- **FILM NUMBER:** 23775931

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 NW 57 COURT, SUITE 400
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33126
- **BUSINESS PHONE:** 786-360-4768

**MAIL ADDRESS:**
- **STREET 1:** 1000 NW 57 COURT, SUITE 400
- **CITY:** MIAMI
- **STATE:** FL
- **ZIP:** 33126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Deerfield Healthcare Technology Acquisitions Corp.
- **DATE OF NAME CHANGE:** 20200602

?xml version="1.0" encoding="ASCII"? 10-Q/A

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

------

**FORM** 10-Q/A

**Amendment No. 1**

------

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended** **September 30,** 2022

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR** **15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number:** 001-39391

------

![img230336080_0.jpg](img230336080_0.jpg)

CareMax, Inc.

**(Exact Name of Registrant as Specified in its Charter)**

------

---

| | |
|:---|:---|
| Delaware | 85-0992224 |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| 1000 NW 57th Court**,** Suite 400<br>Miami**,** FL | 33126 |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (**786**)** 360-4768

------

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Class A common stock, par value $0.0001 per share | CMAX | The Nasdaq Stock Market LLC |
| Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share | CMAXW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

As of November 7, 2022, the registrant had 87,396,972 shares of Class A common stock, $0.0001 par value per share, and no shares of Class B common stock, $0.0001 par value per share issued and outstanding.

------

**EXPLANATORY NOTE**

CareMax, Inc. (the "Company") is filing this Amendment No. 1 on Form 10-Q/A for the quarter ended September 30, 2022 (this "Form 10-Q/A").

This Form 10-Q/A amends the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission ("SEC") on November 9, 2022 (the "Original Filing"). This Form 10-Q/A is being filed to restate the Company's unaudited Condensed Consolidated Financial Statements for the three and nine months ended September 30, 2022. The restatement reflects a correction of the classification of the equity consideration, issued to the Company's real estate advisor in July 2021, from Warrants and prepaid expenses to other assets. See Note 2 to the unaudited Condensed Consolidated Financial Statements included in this Form 10-Q/A for further information regarding the restatement.

The Company is filing this Form 10-Q/A to amend and restate the Original Filing with modification as necessary to reflect the restatement. The following items have been amended to reflect the restatement:

Part I, Item 1: Financial Information

Part I, Item 4: Controls and Procedures

Part II, Item 1A: Risk Factors

Part II, Item 6: Exhibits

In addition, the Company's Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this Form 10-Q/A (Exhibits 31.1, 31.2, 32.1 and 32.2).

Except as described above and set forth in this Form 10-Q/A, this Form 10-Q/A does not amend or update any other information contained in the Original Filing. This Form 10-Q/A does not purport to reflect any information or events subsequent to the Original Filing, except as expressly described herein.

------

**CareMax, Inc.**

**Quarterly Report on Form 10-Q/A**

**For the Quarter Ended September 30, 2022**

**Table of Contents**

---

| | | |
|:---|:---|:---|
| [**<u>PART I.</u>** <u>FINANCIAL INFORMATION</u>](#parti_financial_information) | [**<u>PART I.</u>** <u>FINANCIAL INFORMATION</u>](#parti_financial_information) |  |
| [**<u>Item 1</u>**](#balance_sheets) | [<u>Condensed Consolidated Balance Sheets</u>](#balance_sheets) | 1 |
|  | [<u>Condensed Consolidated Statements of Operations</u>](#statements_operations) | 2 |
|  | [<u>Condensed Consolidated Statements of Changes in Stockholders'/Members' Equity</u>](#statements_equity) | 3 |
|  | [<u>Condensed Consolidated Statements of Cash Flows</u>](#statements_cash_flows) | 5 |
|  | [<u>Notes to Condensed Consolidated Financial Statements</u>](#notes_financial_statements) | 7 |
| [**<u>Item 2.</u>**](#management_discussion_and_analysis) | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#management_discussion_and_analysis) | 21 |
| [**<u>Item 3.</u>**](#quantitative_and_qualitative_risk) | [<u>Quantitative and Qualitative Disclosures About Market Risk</u>](#quantitative_and_qualitative_risk) | 39 |
| [**<u>Item 4.</u>**](#i_item4_controls_procedures) | [<u>Controls and Procedures</u>](#i_item4_controls_procedures) | 40 |
| [**<u>PART II.</u>** <u>OTHER INFORMATION</u>](#partii_other_information) | [**<u>PART II.</u>** <u>OTHER INFORMATION</u>](#partii_other_information) | 41 |
| [**<u>Item 1.</u>**](#ii_itemi_legal_proceedings) | [<u>Legal Proceedings</u>](#ii_itemi_legal_proceedings) | 41 |
| [**<u>Item 1A.</u>**](#ii_itemia_risk_factors) | [<u>Risk Factors</u>](#ii_itemia_risk_factors) | 41 |
| [**<u>Item 2.</u>**](#ii_item2_unregistered_sales_equity) | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#ii_item2_unregistered_sales_equity) | 42 |
| [**<u>Item 3.</u>**](#ii_item3_defaults_senior_securities) | [<u>Defaults Upon Senior Securities</u>](#ii_item3_defaults_senior_securities) | 42 |
| [**<u>Item 4.</u>**](#ii_item4_mine_safety_disclosures) | [<u>Mine Safety Disclosures</u>](#ii_item4_mine_safety_disclosures) | 42 |
| [**<u>Item 5.</u>**](#ii_item5_other_information) | [<u>Other Information</u>](#ii_item5_other_information) | 42 |
| [**<u>Item 6.</u>**](#ii_item6_exhibits) | [<u>Exhibits</u>](#ii_item6_exhibits) | 42 |

---

------

**PART I – FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**CAREMAX, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Unaudited)**

**(in thousands, except share and per share data)**

---

| | | |
|:---|:---|:---|
|  | **September 30, 2022 <br>(As Restated)** | **December 31,<br>2021** |
| **ASSETS** |  |  |
| **Current Assets** |  |  |
| Cash | $53315 | $47917 |
| Accounts receivable, net | 85766 | 41998 |
| Inventory | 911 | 550 |
| Warrants and prepaid expenses | 4757 | 3786 |
| Risk settlements due from providers | 537 | 539 |
| **Total Current Assets** | 145287 | 94790 |
| Property and equipment, net | 18125 | 15993 |
| Goodwill | 465058 | 464566 |
| Intangible assets, net | 48166 | 59811 |
| Deferred debt issuance costs | 2644 | 1972 |
| Other assets | 28154 | 15960 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Assets** | $707433 | $653092 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **Current Liabilities** |  |  |
| Accounts payable | $13422 | $3110 |
| Accrued expenses | 16630 | 8690 |
| Risk settlements due to providers | 50 | 196 |
| Current portion of long-term debt | 159 | 6275 |
| Other current liabilities | 3485 | 3687 |
| **Total Current Liabilities** | 33745 | 21959 |
| Derivative warrant liabilities | 11851 | 8375 |
| Long-term debt | 184253 | 110960 |
| Other liabilities | 8379 | 6428 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Liabilities** | 238228 | 147722 |
| COMMITMENTS AND CONTINGENCIES (NOTE 13) |  |  |
| **STOCKHOLDERS' EQUITY** |  |  |
| Preferred stock (1,000,000 authorized and none outstanding as of September 30, 2022 and December 31, 2021) | - | - |
| Class A common stock ($0.0001 par value; 250,000,000 shares authorized; 87,396,972 and 87,367,972 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively) | 9 | 9 |
| Additional paid-in-capital | 517393 | 505327 |
| Retained earnings (deficit) | (48197) | 33 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Stockholders' Equity** | 469205 | 505370 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Liabilities and Stockholders' Equity** | $707433 | $653092 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(1) ------

**CAREMAX, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited)**

**(in thousands, except share and per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| **Revenue** |  |  |  |  |
| &nbsp;&nbsp;Medicare risk-based revenue | $122267 | $76428 | $373677 | $142005 |
| &nbsp;&nbsp;Medicaid risk-based revenue | 19852 | 20884 | 59914 | 26333 |
| &nbsp;&nbsp;Other revenue | 15551 | 7308 | 33278 | 9118 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 157670 | 104620 | 466869 | 177456 |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;External provider costs | 106900 | 73329 | 320104 | 127023 |
| &nbsp;&nbsp;Cost of care | 30213 | 21602 | 87925 | 34822 |
| &nbsp;&nbsp;Sales and marketing | 2355 | 1274 | 7955 | 2340 |
| &nbsp;&nbsp;Corporate, general and administrative | 21687 | 13589 | 58728 | 24264 |
| &nbsp;&nbsp;Depreciation and amortization | 4573 | 5176 | 14538 | 7127 |
| &nbsp;&nbsp;Acquisition related costs | 494 | 879 | 3549 | 1028 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 166222 | 115849 | 492799 | 196603 |
| &nbsp;&nbsp;**&nbsp;&nbsp;&nbsp;&nbsp; Operating income (loss)** | (8552) | (11229) | (25930) | (19147) |
| **Nonoperating income (expense)** |  |  |  |  |
| &nbsp;&nbsp;Interest expense | (6076) | (1291) | (11700) | (2587) |
| &nbsp;&nbsp;Change in fair value of derivative warrant liabilities | (7331) | 10227 | (3476) | 12022 |
| &nbsp;&nbsp;Gain (loss) on remeasurement of contingent earnout liabilities | - | (11625) | - | 5794 |
| &nbsp;&nbsp;Gain (loss) on extinguishment of debt, net | - | 279 | (6172) | 1637 |
| &nbsp;&nbsp;Other income (expense), net | 87 | (840) | (420) | (840) |
|  | (13320) | (3250) | (21768) | 16026 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Income (loss) before income tax** | (21872) | (14479) | (47698) | (3120) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax benefit (expense) | (181) | - | (532) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $(22053) | $(14479) | $(48230) | $(3120) |
| **Weighted-average basic shares outstanding** | 87408605 | 82552520 | 87415801 | 40847294 |
| **Weighted-average diluted shares outstanding** | 87408605 | 82552520 | 87415801 | 40847294 |
| **Net income (loss) per share** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.25) | $(0.18) | $(0.55) | $(0.08) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.25) | $(0.18) | $(0.55) | $(0.08) |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(2) ------

**CAREMAX, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS'/MEMBERS' EQUITY**

**(Unaudited)**

**(in thousands, except share data)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30, 2021 and 2022** | **Three Months Ended September 30, 2021 and 2022** | **Three Months Ended September 30, 2021 and 2022** | **Three Months Ended September 30, 2021 and 2022** | **Three Months Ended September 30, 2021 and 2022** | **Three Months Ended September 30, 2021 and 2022** | **Three Months Ended September 30, 2021 and 2022** | **Three Months Ended September 30, 2021 and 2022** |
|  | **Class A Common Stock** | **Class A Common Stock** | **Preferred** | **Additional** | **Members'** |  | **Retained Earnings** | **Total** |
|  | **Shares** | **Amount** | **Stock** | **Paid-in-capital** | **units** | **Member's Equity** | **(Deficit)** | **Equity** |
| **BALANCE - JUNE 30, 2021** | 80632457 | $8 | $- | $372088 | $- | $- | $18085 | $390181 |
| Net income (loss) | - | - | - | - | - | - | (14479) | (14479) |
| Reverse recapitalization | - | - | - | (104) | - | - | - | (104) |
| Equity consideration issued to acquire DNF | 2741528 | - | - | 26072 | - | - | - | 26072 |
| Contingently issuable stock to CMG Sellers and IMC Parent - First Share Price Trigger on Earnout Shares | 3200000 | 1 | - | 39109 | - | - | - | 39110 |
| Reclassification of contingent consideration previously liability classified | - | - | - | 45088 | - | - | - | 45088 |
| Proceeds from the sale of Class A common stock, net of offering costs | 500000 | - | - | 6650 | - | - | - | 6650 |
| Stock compensation expense | - | - | - | 966 | - |  | - | 966 |
| Series A Warrants issued under the Advisory Agreement | - | - | - | 12883 | - | - | - | 12883 |
| **BALANCE - SEPTEMBER 30, 2021** | 87073985 | $9 | $- | $502751 | $- | $- | $3605 | $506365 |
| **BALANCE - JUNE 30, 2022** | 87467972 | $9 | $- | $514262 | $- | $- | $(26144) | $488127 |
| Stock-based compensation expense | - | - | - | 3611 | - | - | - | 3611 |
| Cancellation of shares and return of cash held in escrow | (71000) | - | - | (481) | - | - | - | (481) |
| Net income (loss) | - | - | - | - | - | - | (22053) | (22053) |
| **BALANCE - SEPTEMBER 30, 2022** | 87396972 | $9 | $- | $517393 | $- | $- | $(48197) | $469205 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(3) ------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30, 2021 and 2022** | **Nine Months Ended September 30, 2021 and 2022** | **Nine Months Ended September 30, 2021 and 2022** | **Nine Months Ended September 30, 2021 and 2022** | **Nine Months Ended September 30, 2021 and 2022** | **Nine Months Ended September 30, 2021 and 2022** | **Nine Months Ended September 30, 2021 and 2022** | **Nine Months Ended September 30, 2021 and 2022** |
|  | **Class A Common Stock** | **Class A Common Stock** | **Preferred** | **Additional** | **Members'** |  | **Retained Earnings** | **Total** |
|  | **Shares** | **Amount** | **Stock** | **Paid-in-capital** | **units** | **Member's Equity** | **(Deficit)** | **Equity** |
| **BALANCE - DECEMBER 31, 2020** | - | $- | $- | $- | $223 | $6504 | $- | $6727 |
| Activity prior to the Business Combination: |  |  |  |  |  |  |  |  |
| Net income (loss) | - | - | - | - | - | (5185) | - | (5185) |
| Effects of the Business Combination: |  |  |  |  |  |  |  |  |
| Reverse recapitalization | 28780819 | 3 | - | (186632) | (223) | (1319) | 1542 | (186629) |
| Equity consideration issued to acquire IMC | 10412023 | 1 | - | 155346 | - | - | - | 155347 |
| Shares issued for holdback | 55000 | - | - | 821 | - | - | - | 821 |
| Proceeds from the sale of Class A common stock, net of offering costs | 41000000 | 4 | - | 397525 | - | - | - | 397529 |
| Activity after the Business Combination: |  |  |  |  |  |  |  |  |
| Net income (loss) | - | - | - | - | - | - | 2064 | 2064 |
| Equity consideration to acquire SMA | 384615 | - | - | 5027 | - | - | - | 5027 |
| Equity consideration to acquire DNF | 2741528 | - | - | 26072 | - | - | - | 26072 |
| Reverse recapitalization | - | - | - | (104) | - | - | - | (104) |
| Contingently issuable stock to CMG Sellers and IMC Parent - First Share Price Trigger on Earnout Shares | 3200000 | 1 | - | 39109 | - | - | - | 39110 |
| Reclassification of contingent consideration previously liability classified | - | - | - | 45088 | - | - | - | 45088 |
| Proceeds from the sale of Class A common stock, net of offering costs | 500000 | - | - | 6650 | - | - | - | 6650 |
| Stock compensation expense | - | - | - | 966 | - | - | - | 966 |
| Series A Warrants issued under the Advisory Agreement | - | - | - | 12883 | - | - | - | 12883 |
| **BALANCE - SEPTEMBER 30, 2021** | 87073985 | $9 | $- | $502751 | $- | $- | $3605 | $506365 |
| **BALANCE - DECEMBER 31, 2021** | 87367972 | $9 | $- | $505327 | $- | $- | $33 | 505370 |
| Stock-based compensation expense | - | - | - | 7486 | - | - | - | 7486 |
| Issuance of shares upon vesting of stock-based compensation awards | 100000 | - | - | - | - | - | - | - |
| Cancellation of shares and return of cash held in escrow | (71000) | - | - | (481) | - | - | - | (481) |
| Vesting of Series B Warrants under Advisory Agreement | - | - | - | 5060 | - | - | - | 5060 |
| Net income (loss) | - | - | - | - | - | - | (48230) | (48230) |
| **BALANCE - SEPTEMBER 30, 2022** | 87396972 | $9 | $- | $517393 | $- | $- | $(48197) | $469205 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(4) ------

**CAREMAX, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

**(in thousands)**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2022** | **2021** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| Net income (loss) | $(48230) | $(3120) |
| Adjustments to reconcile net income (loss) to net cash |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization expense | 14538 | 7145 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs and discount | 1093 | 522 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 7486 | 966 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative warrant liabilities | 3476 | (12022) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on remeasurement of contingent earnout liabilities | - | (5794) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on extinguishment of debt | 6172 | (1637) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment-in-kind interest expense | 3038 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-cash, net | (242) | - |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | (43109) | 4296 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (361) | 67 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants and prepaid expenses | 292 | (1371) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risk settlements due to (from) providers | (144) | (384) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due to (from) related parties | - | 235 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (1037) | (312) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 9291 | 1583 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 6705 | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 1222 | 1029 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by (used in) operating activities | (39811) | (8801) |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| Purchase of property and equipment | (4862) | (2967) |
| Return of cash held in escrow | 785 | - |
| Acquisition of businesses, net of cash acquired | (892) | (298344) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by (used in) investing activities | (4969) | (301311) |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| Proceeds from issuance of Class A common stock | - | 415000 |
| Issuance costs of Class A common stock | - | (12471) |
| Recapitalization transaction | - | (108386) |
| Proceeds from borrowings | 184000 | 125000 |
| Principal payments on long-term debt | (121926) | (26143) |
| Payments of debt issuance costs | (6456) | (6883) |
| Debt extinguishment costs | - | (487) |
| Collateral for letters of credit | (5439) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by (used in) financing activities | 50179 | 385630 |
| **NET INCREASE IN CASH** | 5399 | 75518 |
| Cash - beginning of period | 47917 | 4934 |
| **CASH - END OF PERIOD** | $53315 | $80451 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(5) ------

**CAREMAX, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)**

**(Unaudited)**

**(in thousands)**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2022** | **2021** |
| **SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES:** |  |  |
| Equity and warrant consideration issued to The Related Companies, L.P. | $5060 | $14533 |
| Equity consideration issued in acquisitions |  | 187266 |
| Contingent consideration issued in business combination |  | 72571 |
| Payroll Protection Program loan forgiveness |  | 2164 |
| Additions to construction in progress funded through accounts payable | 1021 |  |
| Cancellation of shares held in escrow | 821 |  |
| Accrued purchase consideration | 585 |  |
| Equipment acquired through finance leases | 423 |  |
| **SUPPLEMENTAL CASH FLOW INFORMATION:** |  |  |
| Cash paid for interest | 7569 | 2317 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

(6) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(Unaudited)**

**Note 1. DESCRIPTION of business**

CareMax, Inc. ("CareMax" or the "Company"), formerly Deerfield Healthcare Technology Acquisitions Corp. ("DFHT"), a Delaware corporation, was originally formed in July 2020 as a publicly traded special purpose acquisition company for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination involving one or more businesses. CareMax is a technology-enabled care platform providing high-quality, value-based care and chronic disease management through physicians and health care professionals committed to the overall health and wellness continuum of care for its patients. As of September 30, 2022, the Company operated 51 wholly owned, multi-specialty centers in Florida, Tennessee, New York, and Texas that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.

**The Business Combination and Acquisitions**

On December 18, 2020, DFHT entered into a Business Combination Agreement (the "Business Combination Agreement") with CareMax Medical Group, L.L.C., a Florida limited liability company ("CMG"), the entities listed in Annex I to the Business Combination Agreement (the "CMG Sellers"), IMC Medical Group Holdings, LLC, a Delaware limited liability company ("IMC"), IMC Holdings, LP, a Delaware limited partnership ("IMC Parent") and Deerfield Partners, L.P. ("Deerfield Partners"). The Business Combination (as defined below) was approved by DFHT's stockholders and closed on June 8, 2021 (the "Closing Date"), whereby DFHT acquired 100% of the equity interests of CMG and 100% of the equity interests in IMC, with CMG and IMC becoming wholly owned subsidiaries of DFHT. Immediately upon completion (the "Closing") of the transactions contemplated by the Business Combination Agreement and the related financing transactions (the "Business Combination"), the name of the combined company was changed to CareMax, Inc.

Unless the context otherwise requires, "the Company," "we," "us," and "our" refer, for periods prior to the completion of the Business Combination, to CMG and its subsidiaries, and, for periods upon or after the completion of the Business Combination, to CareMax, Inc. and its subsidiaries.

Subsequent to consummation of the Business Combination, primarily during the second half of 2021, the Company acquired Senior Medical Associates, LLC ("SMA"), Stallion Medical Management, LLC ("SMM"), Unlimited Medical Services of Florida, LLC ("DNF"), Advantis Physician Alliance, LLC ("Advantis"), Business Intelligence & Analytics LLC ("BIX"), and three additional businesses (together with the acquisitions of SMA, SMM, DNF, Advantis and BIX, the "Acquisitions") which did not have a material impact on our condensed consolidated financial statements. No significant measurement period adjustments related to the Acquisitions were recognized during the three and nine months ended September 30, 2022 and 2021. Refer to Note 4 for information about measurement period adjustments recognized in 2022.

**Pending Steward Transaction** 

In May 2022, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among (i) the Company, (ii) Sparta Merger Sub I Inc., a Delaware corporation and wholly-owned subsidiary of the Company, (iii) Sparta Merger Sub II Inc., a Delaware corporation and wholly-owned subsidiary of the Company, (iv) Sparta Merger Sub III Inc., a Delaware corporation and wholly-owned subsidiary of the Company, (v) Sparta Merger Sub I LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company, (vi) Sparta Merger Sub II LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company, (vii) Sparta Merger Sub III LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company, (viii) Sparta Sub Inc., a Delaware corporation ("SACN Holdco"), (ix) SNCN Holdco Inc. a Delaware corporation ("SNCN Holdco"), (x) SICN Holdco Inc., a Delaware corporation ("SICN Holdco" and, collectively with SACN Holdco, SNCN Holdco, Steward National Care Network, Inc., Steward Integrated Care Network, Inc., and Steward Accountable Care Network, Inc., each a "target" and, collectively, the "Targets"), (xi) Sparta Holding Co. LLC, a Delaware limited liability company (the "Seller"), and (xii) Steward Health Care System LLC, a Delaware limited liability company (referred to collectively with the Seller, the "Seller Parties"), pursuant to which the Company will acquire the Medicare value-based care business of the Seller Parties (such transaction, the "Steward Transaction").

The aggregate consideration to be paid to the Seller at closing includes cash payment of $25 million, subject to customary adjustments, and 23,500,000 shares, subject to adjustment, of the Company's Class A common stock, $0.0001 par value per share ("Class A Common Stock"). In addition, the Merger Agreement provides for earnout share consideration that will be due

(7) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

to the Seller upon achievement of certain milestones. At closing, the Company will also issue to certain equityholders of the Seller shares of a newly designated series of preferred stock of the Company, which will provide voting rights to such Seller equityholders, until the earlier of (i) the two year anniversary of the closing of the Steward Transaction and (ii) the issuance of earnout share consideration on certain discrete matters where such Seller equityholders are permitted to vote the Company's securities in their discretion under the investor rights agreement to be entered into between such equityholders of the Seller and the Company. Finally, at closing, the Company will also pay the Seller an amount equal to the value of the Target's accounts receivable attributable to Medicare value-based payments for the period between January 1, 2021 and the closing, minus the amount of such payments payable to the affiliate physicians of the Targets (the "Financed Net Pre-Closing Medicare AR").

During the three and nine months ended September 30, 2022, we have recognized $0.5 million and $3.5 million, respectively, of acquisition costs related to the pending Steward Transaction. We will continue to incur acquisition costs, including $8 million in fees to a financial advisor, payment of $3 million of which is contingent upon closing of the Steward Transaction, and payment of $5 million of which is contingent upon payment of the earnout share consideration to the Seller Parties. We will reflect this $8 million fee in our financial statements during the period in which the Steward Transaction closes.

**Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation and Principles of Consolidation**

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP has been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. The condensed consolidated balance sheet at December 31, 2021, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements. Accordingly, the unaudited condensed consolidated financial statements should be read in connection with the Company's audited financial statements and related notes as of and for the year ended December 31, 2021 as filed with the SEC on March 16, 2022.

Certain amounts in prior period financial statements have been reclassified to conform to the current period presentation. Such reclassifications have not materially affected previously reported amounts. In the opinion of management, the accompanying unaudited and condensed consolidated financial statements include all adjustments of a normal recurring nature, which are necessary for a fair statement of financial position, operating results and cash flows for the periods presented. Operating results for any interim period are not necessarily indicative of results for the full year.

Pursuant to the Business Combination, the acquisition of CMG by DFHT was accounted for as a reverse recapitalization in accordance with GAAP (the "Reverse Recapitalization"). Under this method of accounting, DFHT was treated as the "acquired" company. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of CMG issuing equity for the net assets of DFHT, accompanied by a recapitalization. The net assets of DFHT were stated at historical cost, with no goodwill or other intangible assets recorded. Further, CMG was determined to be the accounting acquirer in the acquisition of IMC (the "IMC Acquisition"). As such, the acquisition was considered a business combination under Accounting Standard Codification ("ASC") Topic 805, Business Combinations, and was accounted for using the acquisition method of accounting. CareMax recorded the fair value of assets acquired and liabilities assumed from IMC.

Unless otherwise noted, information for periods prior to the Closing Date reflects the financial information of CMG only.

The condensed consolidated financial statements include the accounts and operations of the Company. All intercompany accounts and transactions have been eliminated.

**Restatement of Previously Reported Financial Statements**

In conjunction with the Company's close process for the year ended December 31, 2022, management identified an error related to classification of equity consideration issued to the Company's real estate advisor in July 2021 (the "Prepaid Asset"). The Prepaid Asset was previously presented as part of the Company's short-term assets, in Warrants and prepaid expenses. The Company determined that the Prepaid Asset relates to services that are performed by the real estate advisor over multiple years.

(8) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

Accordingly, the Prepaid Asset should be recorded in other assets, except for the portion that represents the Prepaid Asset amortization expense expected to be recognized during the next twelve months following a given period.

The following table reflects the impact of the restatement to the specified line items presented in the Company's previously reported unaudited condensed consolidated balance sheet as of September 30, 2022:

---

| | | | |
|:---|:---|:---|:---|
| (in thousands) | **As Originally Reported** | **Adjustment** | **As Restated** |
| **ASSETS** |  |  |  |
| **Affected financial statement line items** |  |  |  |
| Warrants and prepaid expenses | 21653 | (16896) | 4757 |
| **Total Current Assets** | $162183 | $(16896) | $145287 |
| Other assets | 11258 | 16896 | 28154 |

---

There was no impact on the condensed consolidated statement of operations, statements of changes in stockholders'/members' equity or statement of cash flows.

The accompanying applicable Notes have been updated to reflect the restatement described above.

(9) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

**Segment Financial Information**

The Company's chief operating decision maker regularly reviews financial operating results on a condensed consolidated basis for purposes of allocating resources and evaluating financial performance. The Company identifies operating segments based on this review by its chief operating decision maker and operates in and reports as a single operating segment, the objective of which is to care for its patients' needs. For the periods presented, all of the Company's long-lived assets were located in the United States, and all revenue was earned in the United States.

**Significant Accounting Policies**

Other than addition of the Variable Interest Entity policy, there have been no changes to our significant accounting policies and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 16, 2022.

**Variable Interest Entities**

The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity ("VIE"). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the VIE. The Company consolidates VIEs when it is determined that the Company is the primary beneficiary of the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company's involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. Refer to Note 14 "Variable Interest Entities" for additional information.

**Use of Estimates**

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed. The Company bases its estimates on the available information, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The areas where significant estimates are used in the accompanying financial statements include, but are not limited to, revenues and related receivables from risk adjustments, medical services expense and related payables, purchase price allocations, including fair value estimates of intangibles and contingent consideration; the valuation of and related impairment testing of long-lived assets, including goodwill and intangible assets; the valuation of derivative warrant liabilities; the estimated useful lives of fixed assets and intangible assets, including internally developed software; revenue recognition and liability for unpaid claims. Actual results could differ from those estimates.

**Emerging Growth Company**

Section 102(b)(1) of the Jumpstart Our Business Startups Act (the "JOBS Act") exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to nonemerging growth companies, but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company's condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Additionally, as an emerging growth company, the Company is exempt from the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended, and the Company's independent registered public accounting firm is not required to evaluate and report on the effectiveness of internal control over financial reporting.

(10) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

**Concentration of Credit Risk and Significant Customers**

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and accounts receivable. The Company's cash balances with individual banking institutions are in excess of federally insured limits from time to time. The Company has not experienced any losses on its deposits of cash and cash equivalents.

Composition of the Company's revenues and accounts receivable balances for the payors comprising 10% or more of revenue was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Total Revenue** | **Total Revenue** | **Total Revenue** | **Total Revenue** |
|  | **Three months ended September 30, 2022** | **Nine months ended September 30, 2022** | **Three months ended September 30, 2021** | **Nine months ended September 30, 2021** |
| Payor A | 30% | 30% | 46% | 51% |
| Payor B | 19% | 19% | n/a | n/a |
| Payor C | 16% | 17% | n/a | n/a |
| Payor D | 13% | 14% | n/a | n/a |
| Payor E | 11% | 12% | n/a | n/a |

---

---

| | | |
|:---|:---|:---|
|  | **Accounts Receivable, net** | **Accounts Receivable, net** |
|  | **As of September 30, 2022** | **As of December 31, 2021** |
| Payor A | 24% | 27% |
| Payor B | 22% | n/a |
| Payor C | 20% | 12% |
| Payor D | 19% | 23% |
| Payor E | 12% | 15% |

---

Allowance for doubtful accounts was less than $0.1 million as of September 30, 2022 and December 31, 2021.

**Recent Accounting Pronouncements**

The Company has elected to defer compliance with ASC Topic 842, Leases ("ASC 842"), consistent with those requirements for a private company due to the Company's status as an emerging growth company and the provisions of the JOBS Act. Accordingly, the Company adopted ASC 842 for the annual reporting period beginning January 1, 2022, and interim reporting periods within the annual reporting period beginning after December 15, 2022. As such, the Company has continued to present accounting for leases in its condensed consolidated financial statements in accordance with ASC Topic 840, Leases, in this Quarterly Report on Form 10-Q/A. The effect of adoption to be presented in the Company's 2022 Form 10-K is expected to add approximately $0.1 billion right of use assets and corresponding lease liabilities to the Company's balance sheet as of January 1, 2022.

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, "Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments", which was subsequently amended by ASU 2020-03, "Codification Improvements to financial Instruments" (collectively referred to as "ASC 326"), which is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. This standard replaces the previous incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is acquired or purchased. The standard has been further refined through subsequent releases by the FASB. The Company adopted ASC 326 on January 1, 2022 with no material impact to the consolidated financial statements.

In March 2020, the FASB issued temporary guidance to ease the potential burden in accounting for reference rate reform primarily resulting from the discontinuation of LIBOR. In addition, in January 2021, the FASB issued guidance which refined the scope of ASC Topic 848, Reference Rate Reform, and clarified some of its guidance as part of FASB's ongoing monitoring of global reference rate reform activities. This guidance permitted entities to elect certain optional expedients and exceptions when accounting for derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, computing variation margin settlements and calculating price alignment interest in connection with reference rate reform activities under way in global financial markets. An entity may apply these amendments prospectively through December 31, 2022. The Company is currently evaluating the effect the update will have on its consolidated financial statements and related disclosures.

(11) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

In October 2021, the FASB issued ASU 2021-08, "Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." The ASU improves comparability after business combinations by providing consistent recognition and measurement guidance for revenue contracts with customers acquired in a business combination and revenue contracts with customers not acquired in a business combination. ASU 2021-08 is effective for the Company on January 1, 2023, with early adoption permitted. This standard will not impact acquired contract assets or liabilities from business combinations occurring prior to the effective date of adoption, and the impact in the future periods will depend on the contract assets and contract liabilities acquired in future business combinations. The Company will adopt this guidance with respect to business combinations taking place after January 1, 2023, the effective date of this guidance.

**NOTE 3. REINSURANCE**

The Company has acquired insurance on catastrophic costs to limit the exposure on patient losses. Premiums and policy recoveries are reported in external provider costs in our condensed consolidated statements of operations.

The nature of the Company's stop loss coverage is to limit the benefits paid under one patient. The Company's stop loss limits are defined within each health plan contract and stop loss purchased from a third party and can range from $30,000 to $200,000 per patient per year. Premiums incurred were $5.8 million and $13.7 million for the three and nine months ended September 30, 2022, respectively and $3.3 million and $5.5 million for the three and nine months ended September 30, 2021, respectively. Physicians under capitation arrangements typically have stop loss coverage so that a physician's financial risk for any single member is limited to a maximum amount on an annual basis. The Company monitors the financial performance and solvency of its stop loss providers. However, the Company remains financially responsible for health care services to its members in the event the health plans are unable to fulfill their obligations under stop loss contractual terms.

Recoveries recognized were $6.9 million and $21.0 million for the three and nine months ended September 30, 2022, respectively, and $5.2 million and $6.9 million for the three and nine months ended September 30, 2021, respectively. Estimated recoveries under stop loss policies are reported within the accounts receivable, net, or amounts due to health plans as the counterparty responsible for the payment of the claims and the stop loss is the respective health plan.

**NOTE 4. GOODWILL AND INTANGIBLE ASSETS**

**Goodwill**

The following table summarizes changes in the carrying amount of goodwill for the nine months ended September 30, 2022 (in thousands):

---

| | |
|:---|:---|
|  | **Carrying Amount** |
| Balance at December 31, 2021 | $464566 |
| Goodwill acquired | 1478 |
| Measurement period adjustments and other | (986) |
| Balance at September 30, 2022 | $465058 |

---

In August and September 2022, we acquired two medical practices for total consideration of $1.5 million and recognized related goodwill in the amount of $1.5 million.

**Intangible Assets**

The following tables summarize gross carrying amounts and accumulated amortization of intangible assets by major class (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Gross Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net Book<br>Value** | **Weighted-Average<br>Amortization Period (years)** |
| **September 30, 2022** |  |  |  |  |
| Risk contracts | $64570 | $(20057) | $44512 | 7 |
| Non-compete agreements | 4170 | (1309) | 2861 | 5 |
| Trademarks | 1862 | (1273) | 589 | 2 |
| Other | 251 | (47) | 204 | 5 |
| Total | $70852 | $(22687) | $48166 |  |

---

(12) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Gross Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net Book<br>Value** | **Weighted-Average<br>Amortization Period (years)** |
| **December 31, 2021** |  |  |  |  |
| Risk contracts | $64822 | $(9818) | $55004 | 7 |
| Non-compete agreements | 4202 | (686) | 3516 | 5 |
| Trademarks | 1867 | (827) | 1040 | 2 |
| Other | 251 |  | 251 | 5 |
| Total | $71141 | $(11331) | $59811 |  |

---

Amortization expense totaled $3.7 million and $11.4 million for the three and nine months ended September 30, 2022 and $4.2 million and $5.5 million for the three and nine months ended September 30, 2021, respectively.

**NOTE 5. PROPERTY AND EQUIPMENT**

A summary of property and equipment at September 30, 2022 and December 31, 2021 is as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30, 2022** | **December 31, 2021** |
| Leasehold improvements | $10229 | $7516 |
| Vehicles | 3743 | 3711 |
| Furniture and equipment | 7825 | 5470 |
| Software | 3618 | 2950 |
| Construction in progress | 1536 | 2254 |
| Total | 26951 | 21902 |
| Less: Accumulated depreciation | (8826) | (5909) |
| Total Property and equipment, net | $18125 | $15993 |

---

Construction in progress at September 30, 2022 consisted of various leasehold improvements at the Company's centers.

Depreciation expense totaled $0.9 million and $3.2 million for the three and nine months ended September 30, 2022, respectively, and $1.0 million and $1.7 million during the three and nine months ended September 30, 2021, respectively.

**NOTE 6. DEBT**

In May 2022, the Company entered into a credit agreement (the "Credit Agreement") that provided for an aggregate of up to $300 million in term loans, comprised of (i) initial term loans in aggregate principal amount of $190 million (the "Initial Term Loans") and (ii) a delayed term loan facility in the aggregate principal amount of $110 million (the "Delayed Draw Term Loans"). The Credit Agreement permits the Company to enter into certain incremental facilities subject to compliance with the terms, conditions and covenants set forth therein. In May 2022, the Company drew $190 million of the Initial Term Loans and used approximately $121 million of the net proceeds from this borrowing to repay its outstanding obligations under the credit agreement dated June 8, 2021, as amended (the "Existing Credit Agreement"). During the nine months ended September 30, 2022, the Company recognized debt extinguishment losses of $6.2 million related to early repayment of the Existing Credit Agreement. No debt extinguishment gains or losses were recognized during the three months ended September 30, 2022.

Based on the elections made by the Company, as of September 30, 2022, the Initial Term Loan borrowings bear interest of Term SOFR (calculated as the Secured Overnight Financing Rate published on the Federal Reserve Bank of New York's website, plus a spread adjustment of 0.114%), plus an applicable margin rate of 9.00%. As permitted under the Credit Agreement, the Company elected to capitalize 4.00% of the interest as principal amount on the outstanding Term Loans. As a result of this election, the cash interest component of the applicable margin increases by 0.50%. During the nine months ended September 30, 2022, the Company paid-in-kind $3.0 million of the interest payable under the Credit Agreement, which resulted in an increase to long-term debt.

Amortization payments under the Credit Agreement are payable in quarterly installments, commencing on March 31, 2024, in aggregate principal amounts equal to 0.25% of the original aggregate principal amount of Initial Term Loans and Delayed Draw Term Loans. As of September 30, 2022, no amounts have been borrowed under the Delayed Draw Term Loans. All amounts owed under the Credit Agreement are due in May 2027.

(13) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

The Credit Agreement contains certain covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, liens or encumbrances, to make certain investments, to enter into sale-leaseback transactions or sell certain assets, to make certain restricted payments or pay dividends, to enter into consolidations, to transact with affiliates and to amend certain agreements, subject in each case to the exceptions and other qualifications as provided in the Credit Agreement. The Credit Agreement also contains covenants that require the Company to satisfy a minimum liquidity requirement of $50.0 million, which may be decreased to $25.0 million if the Company achieves a certain adjusted EBITDA, and maintain a maximum total leverage ratio based on the Company's consolidated EBITDA, as defined in the Credit Agreement, with de novo losses excluded from the calculation of such ratio for up to 36 months after the opening of a de novo center, which maximum total leverage ratio will initially be 8.50 to 1.00, commencing with the fiscal quarter ended September 30, 2022 and is subject to a series of step-downs. For the fiscal quarters ending September 30, 2026 and thereafter the Company must maintain a maximum total leverage ratio no greater than 5.50 to 1.00.

As of September 30, 2022 and December 31, 2021, debt consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30, 2022** | **December 31, 2021** |
| Secured term loans | $193038 | $121875 |
| Other | 596 | 65 |
| Less: Unamortized discounts and debt issuance costs | (9223) | (4704) |
|  | 184413 | 117236 |
| Less: Current portion | (159) | (6275) |
| Long-term portion | $184253 | $110960 |

---

Fair value of debt as of September 30, 2022 was $199.0 million, calculated using Level 3 measurements.

Future maturities of debt outstanding at September 30, 2022 were as follows (in thousands):

---

| | |
|:---|:---|
| **Year** | **Amount** |
| Remainder of 2022 | $39 |
| 2023 | 161 |
| 2024 | 2090 |
| 2025 | 2040 |
| 2026 | 1993 |
| Thereafter | 187311 |
| Total | $193634 |

---

**NOTE 7. STOCKHOLDERS' EQUITY**

The condensed consolidated statement of changes in stockholders' equity reflects the Reverse Recapitalization discussed in Note 2. As CMG was deemed the accounting acquirer in the Reverse Recapitalization with DFHT, all periods prior to the consummation of the Business Combination reflect the balances and activity of CMG.

**Related Advisory Agreement**

On July 13, 2021, the Company entered into an exclusive real estate advisory agreement (the "Advisory Agreement") with Related CM Advisor, LLC (the "Advisor"), a Delaware limited liability company and a subsidiary of The Related Companies, L.P. ("Related"), pursuant to which the Advisor has agreed provide certain real estate advisory services to the Company on an exclusive basis. The services include identifying locations for new centers nationwide as part of the Company's de novo growth strategy, including, but not limited to, locations within and proximate to affordable housing communities that may be owned by Related.

In connection with the Advisory Agreement, the Company and the Advisor entered into a subscription agreement (the "Subscription Agreement"), whereby the Advisor purchased 500,000 shares (the "Initial Shares") of the Company's Class A Common Stock for an aggregate purchase price of $5.0 million and the Company issued to the Advisor (i) a warrant (the "Series A Warrant") to purchase 2,000,000 shares of Class A Common Stock (the "Series A Warrant Shares"), which vested immediately upon issuance, is exercisable for a period of five years and is not redeemable by the Company and (ii) a warrant (the "Series B Warrant" and together with the Series A Warrant, the "Warrants") to purchase up to 6,000,000 shares of Class A Common Stock (the "Series B Warrant Shares" and, together with the Series A Warrant Shares, the "Warrant Shares"), pursuant to which 500,000 Series B Warrant Shares will vest and become exercisable from time to time upon the opening of each center under the Advisory Agreement for which the Advisor provides services, other than two initial centers.

(14) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

The Company assessed the substance of the Subscription Agreement and determined that all instruments referenced in the Subscription Agreement should be assessed under the guidance of ASC Topic 718, Compensation - Stock Compensation, as non-employee awards issued to Related in exchange for real estate advisory services to be rendered per the Advisory Agreement. As a result, the Company recorded the Series A Warrants as a component of additional paid-in-capital using the fair value as of July 13, 2021.

The Series B Warrant is exercisable, to the extent vested, until the later of five years from the date of issuance or one year from vesting of the applicable Series B Warrant Shares and is redeemable with respect to vested Warrant Shares at a price of $0.01 per Warrant Share if the price of the Class A Common Stock equals or exceeds $18.00 per share, or $0.10 per Warrant Share if the price of the Class A Common Stock equals or exceeds $10.00 per share, in each case when such price conditions are satisfied for any 20 trading days within a 30-trading day period and subject to certain adjustments and conditions as described in the Series B Warrant. In the event that the Series B Warrant is called for redemption by the Company, the Advisor may pay the exercise price for the Series B Warrant Shares six months following the notice of redemption by the Company.

Series B Warrants are recognized at their grant date fair value once vesting becomes probable. During the nine months ended September 30, 2022, the Company recorded $5.0 million, which represents the fair value of vested Series B Warrants, in other assets, except for the portion that represents Series B Warrant amortization expected to be recognized during the next twelve months, which is recorded in Warrants and prepaid expenses, to reflect vesting of 1,000,000 Series B Warrant Shares. Refer to Note 10, Related Party Transactions, for additional information. No Series B Warrants vested during the three months ended September 30, 2022.

**Preferred Stock**

The Company's Third Amended and Restated Certificate of Incorporation, dated June 8, 2021, authorizes the Company to issue 1,000,000 shares of preferred stock, with such designations, voting and other rights and preferences as may be determined from time to time by the Company's board of directors. As of September 30, 2022, there were no shares of preferred stock issued or outstanding.

**Redeemable Warrants - Public Warrants**

On July 16, 2020, in connection with the Company's initial public offering (the "IPO"), DFHT sold 2,875,000 Public Warrants. Each whole Public Warrant entitles the registered holder to purchase one share of Class A Common Stock at a price of $11.50 per share, subject to adjustment, at any time commencing on the later of 12 months from the closing of the IPO and 30 days after the completion of the Business Combination, provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of Class A Common Stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis under the circumstances specified in the warrant agreement) and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the warrant agreements entered into at the time of the IPO, a warrant holder may exercise its Public Warrants only for a whole number of shares of Class A Common Stock. This means only a whole Public Warrant may be exercised at a given time by a warrant holder. No fractional warrants were issued upon separation of the units issued in connection with the IPO and only whole Public Warrants will trade. The Company may redeem the Public Warrants when the price per share of Class A Common Stock equals or exceeds certain threshold prices. As of September 30, 2022, none of the Public Warrants have been redeemed.

**Redeemable Warrants - Private Placement Warrants**

Also in connection with the IPO, DFHT issued the 2,916,667 Private Placement Warrants at a purchase price of $1.50 per warrant. The Private Placement Warrants will not be redeemable by CareMax for cash so long as they are held by the initial stockholders or their permitted transferees. With some exceptions, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants. If the Private Placement Warrants are held by holders other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. As of September 30, 2022, none of the Private Placement Warrants have been redeemed.

(15) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

**Contingent Consideration Common Shares**

Pursuant to the Business Combination Agreement, the CMG Sellers and IMC Parent, who received Class A Common Stock in connection with the Business Combination, are entitled to receive earn-out consideration to be paid out in the form of Class A Common Stock. The Business Combination Agreement provides that up to an additional 3,500,000 and 2,900,000 contingently issuable shares of Class A Common Stock (the "Earnout Shares") are payable after the Closing to the CMG Sellers and IMC Parent: (i) if within the first year after the Closing, the volume weighted-average trading price of Class A Common Stock equals or exceeds $12.50 on any 20 trading days in any 30-day trading period (the "First Share Price Trigger"), then 1,750,000 and 1,450,000 Earnout Shares are issuable to the CMG Sellers and IMC Parent, respectively, and (ii) if within the two years after the Closing (the "Second Earnout Period"), the volume weighted-average trading price of Class A Common Stock equals or exceeds $15.00 on any 20 trading days in any 30-day trading period (the "Second Share Price Trigger" and together with the First Share Price Trigger, the "Share Price Triggers"), then 1,750,000 and 1,450,000 Earnout Shares will be issued to the CMG Sellers and IMC Parent, respectively. If prior to (i) the satisfaction of the Share Price Triggers, and (ii) the end of the Second Earnout Period, the Company enters into a change in control transaction as described in the Business Combination Agreement, and the price per share of the Company's Class A Common Stock payable to the stockholders of the Company in such change in control transaction is greater than the Share Price Triggers that have not been satisfied during the Earnout Period, then at the closing of such change in control transaction, the Share Price Triggers will be deemed to have been satisfied and the Company is required to issue, as of such closing, the applicable unissued Earnout Shares. The estimated fair value of the Earnout Shares was initially accounted for as a liability-classified instrument with changes in its fair value recorded in our condensed consolidated statements of operations until July 9, 2021. On July 9, 2021, the First Share Price Trigger was achieved, resulting in issuance of 1,750,000 and 1,450,000 Earnout Shares to the CMG Sellers and IMC Parent, respectively. Subsequent to the achievement of the First Share Price Trigger, the Company determined the Earnout Shares subject to the second Share Price Trigger should be equity classified and were recorded as such on July 9, 2021, the date of the event that caused the reclassification. As of September 30, 2022, the Second Share Price Trigger has not been achieved.

**Stock-Based Compensation**

On June 4, 2021, the stockholders of the Company approved the CareMax, Inc. 2021 Long-term Incentive Plan (the "2021 Plan"), effective on the Closing Date. The 2021 Plan permits the grant of equity-based awards to officers, directors, employees and other service providers. The 2021 Plan permits the grant of an initial share pool of 7,000,000 shares of Class A Common Stock and will be increased automatically, without further action of the Company's board of directors, on January 1st of each calendar year commencing after the Closing Date and ending on (and including) January 1, 2031, by a number of shares of Class A Common Stock equal to the lesser of (i) four percent of the aggregate number of shares of Class A Common Stock outstanding on December 31st of the immediately preceding calendar year, excluding for this purpose any such outstanding shares of Class A Common Stock that were granted under the 2021 Plan and remain unvested and subject to forfeiture as of the relevant December 31st, or (ii) a lesser number of shares of Class A Common Stock as determined by the Company's board of directors or the Compensation Committee of the board of directors prior to the relevant January 1<sup>st</sup>.

The following awards were granted under the 2021 Plan during the three and nine months ended September 30, 2022:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended September 30, 2022** | **Three Months Ended September 30, 2022** |
|  | **Number of units** | **Weighted-average grant date fair value** |
| Restricted stock units | 55498 | $7.74 |
| Performance stock units | - | $- |
| Options | - | $- |
|  | **Nine Months Ended September 30, 2022** | **Nine Months Ended September 30, 2022** |
|  | **Number of units** | **Weighted-average grant date fair value** |
| Restricted stock units | 2069535 | $8.31 |
| Performance stock units | 123739 | $5.56 |
| Options | 247483 | $6.13 |

---

During the three and nine months ended September 30, 2022, the Company recorded stock-based compensation expense of $3.6 million and $7.5 million, respectively. As of September 30, 2022, the Company had $22.3 million of unrecognized compensation expense for awards that will vest over the weighted-average period of 2.3 years.

(16) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

During the three and nine months ended September 30, 2021, 100,000 shares of Class A Common Stock were issued and related stock-based compensation expense of $1.0 million was recognized. There were no unvested awards outstanding as of September 30, 2021.

Stock-based compensation expense is included in the corporate, general and administrative expenses in our condensed consolidated statements of operations.

**NOTE 8. NET INCOME (LOSS) PER SHARE**

The Business Combination was accounted for as a reverse recapitalization by which CMG issued equity for the net assets of the Company accompanied by a recapitalization. Earnings per share have been recast for all historical periods to reflect the Company's capital structure for all comparative periods.

The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted-average number of common shares outstanding for the period subsequent to the transactions that occurred in connection with the Business Combination (in thousands, except share and per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Net income (loss) attributable to CareMax, Inc. class A common stockholders | $(22053) | $(14479) | $(48230) | $(3120) |
| Weighted-average basic shares outstanding | 87408605 | 82552520 | 87415801 | 40847294 |
| Weighted-average diluted shares outstanding | 87408605 | 82552520 | 87415801 | 40847294 |
| Net income (loss) per share |  |  |  |  |
| Basic | $(0.25) | $(0.18) | $(0.55) | $(0.08) |
| Diluted | $(0.25) | $(0.18) | $(0.55) | $(0.08) |

---

The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share because their effect would have been anti-dilutive or because issuance of shares underlying such securities is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Series A and Series B Warrants | 8000000 | 8000000 | 8000000 | 8000000 |
| Public and Private Placement Warrants | 5791652 | 5791652 | 5791652 | 5791652 |
| Earnout Shares | 3200000 | 3200000 | 3200000 | 3200000 |
| Unvested restricted stock units | 3163790 |  | 3163790 |  |
| Unvested performance stock units (assumes 100% target payout) | 189389 |  | 189389 |  |
| Unvested options | 378783 |  | 378783 |  |
| Total | 20723614 | 16991652 | 20723614 | 16991652 |

---

**NOTE 9. FAIR VALUE MEASUREMENTS**

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value (in thousands):

---

| | | | |
|:---|:---|:---|:---|
| **September 30, 2022** | **Quoted Prices<br>in Active<br>Markets** | **Significant other<br>Observable<br>Units** | **Significant other<br>Unobservable<br>Units** |
| **Description** | **(Level 1)** | **(Level 2)** | **(Level 3)** |
| Derivative warrant liabilities - Public Warrants | $5405 | $— | $— |
| Derivative warrant liabilities - Private Placement Warrants | $— | $— | $6446 |

---

(17) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| **December 31, 2021** | **Quoted Prices<br>in Active<br>Markets** | **Significant other<br>Observable<br>Units** | **Significant other<br>Unobservable<br>Units** |
| **Description** | **(Level 1)** | **(Level 2)** | **(Level 3)** |
| Derivative warrant liabilities - Public Warrants | $— | $— | $4375 |
| Derivative warrant liabilities - Private Placement Warrants | $— | $— | $4000 |

---

Fair value of the Private Placement Warrants is measured using a Monte Carlo simulation model, which is considered to be a Level 3 fair value measurement. Key inputs into the Monte Carlo simulation include the expected stock price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its common stock after considering the historical volatility of select peer companies that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.

The fair value of Public Warrants is measured using the listed market price of such warrants, which is considered to be a Level 1 fair value measurement.

During the three and nine months ended September 30, 2022, the Company recognized a loss resulting from an increase in the fair value of derivative warrant liabilities of $7.3 million and $3.5 million, respectively. During the three and nine months ended September 30, 2021, the Company recognized gains of $10.2 million and 12.0 million, respectively.

There were no transfers between levels during the three and nine months ended September 30, 2022 or during the three and nine months ended September 30, 2021.

The following table provides quantitative information regarding Level 3 fair value measurements inputs used in measurement of fair value of Private Placement Warrants:

---

| | | |
|:---|:---|:---|
|  | **September 30,<br>2022** | **December 31, 2021** |
| Exercise price | $11.50 | $11.50 |
| Unit price | $7.09 | $7.68 |
| Volatility | 55.7% | 37.6% |
| Expected life of the options to convert (years) | 3.69 | 4.44 |
| Risk-free rate | 4.10% | 1.17% |
| Dividend yield | 0.0% | 0.0% |

---

The change in the fair value of derivative warrant liabilities for the nine months ended September 30, 2022 is summarized as follows (in thousands):

---

| | |
|:---|:---|
| Fair value of derivative warrant liabilities at December 31, 2021 | $8375 |
| Change in fair value of derivative warrant liabilities | 3476 |
| Fair value of derivative warrant liabilities at September 30, 2022 | $11851 |

---

**NOTE 10. RELATED PARTY TRANSACTIONS**

On July 13, 2021, the Company entered into the Advisory Agreement with the Advisor, which is described in Note 7, Stockholders' Equity.

On July 13, 2021, the Company's board of directors appointed Mr. Bryan Cho, an Executive Vice President of Related, to serve as a Class III director of the Company. The appointment of Mr. Bryan Cho was made in connection with the Advisory Agreement, which provides the Advisor with the right to designate a director to serve on the Company's board of directors, subject to the continuing satisfaction of certain conditions, including that the Advisor and its affiliates maintain ownership of at least 500,000 shares of Class A Common Stock.

During the nine months ended September 30, 2022, the Company recognized vesting of 1,000,000 Series B Warrant Shares related to two centers for which the Advisor provided services under the Advisory Agreement. Refer to Note 7, Stockholders' Equity, for additional information. In addition, during the three and nine months ended September 30, 2022, we have recorded

(18) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

$0 and $0.4 million, respectively, in construction in progress representing construction advisory services provided to us by Related (none in 2021).

**NOTE 11. OPERATING LEASES AND COMMITMENTS**

The Company has entered into non-cancelable operating lease agreements for office space and centers expiring at various times through 2033. The operating lease agreements have renewal options ranging from one to seven years. Future minimum rental payments under these lease agreements, including renewal options which are considered reasonably certain of exercise and inclusive of leases which have not yet commenced, consisted of the following at September 30, 2022 (in thousands):

---

| | |
|:---|:---|
| **Year** | **Amount** |
| Remainder of 2022 | $3786 |
| 2023 | 18309 |
| 2024 | 19192 |
| 2025 | 18959 |
| 2026 | 18170 |
| Thereafter | 208556 |
| Total | $286973 |

---

Rent expense, including related property taxes, sales taxes, and utilities, was $4.6 million and $12.7 million during the three and nine months ended September 30, 2022, respectively, and $2.8 million and $4.4 million during the three and nine months ended September 30, 2021, respectively. Rent expense is included in corporate, general and administrative expenses and in cost of care in our condensed consolidated statements of operations.

**NOTE 12. INCOME TAXES**

Prior to the completion of the Business Combination, CMG was a limited liability company and treated as a partnership for federal and state income tax purposes. A partnership is not a tax-paying entity for federal and state income tax purposes, and as such, the results of operations were allocated to the members for inclusion in their income tax returns. Following the Business Combination, the income of CMG flows through to the Company and is taxed at the federal and state levels accordingly.

Income tax expense was $0.2 million and $0.5 million during the three and nine months ended September 30, 2022, respectively, and the Company did not have any tax expense during the three and nine months ended September 30, 2021. The effective tax rate was (0.8)% and (1.1)% during the three and nine months ended September 30, 2022, respectively, and 0.0% during the three and nine months ended September 30, 2021, based on the assessment of a full valuation allowance, excluding a portion attributable to the "naked credit" deferred tax liability.

**NOTE 13. COMMITMENTS AND CONTINGENCIES**

**Compliance**

The health care industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Recently, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with imposition of significant fines and penalties, as well as significant repayments for patient services billed. Compliance with these laws and regulations, specifically those related to the Medicare and Medicaid programs, can be subject to government review and interpretation, as well as regulatory actions unknown and not yet asserted at this time. Management believes that the Company is in substantial compliance with current laws and regulations.

**Litigation**

The Company is involved in various legal actions arising in the normal course of business. Management has not identified any legal actions that were deemed to be material, during the three and nine months ended September 30, 2022, or during the three and nine months ended September 30, 2021.

**NOTE 14. VARIABLE INTEREST ENTITIES**

(19) ------

**CAREMAX, inc.**

**NOTES TO condensed consolidated FINANCIAL STATEMENTS**

**(unaudited)**

Medical Care of NY, P.C., Medical Care of Tennessee, PLLC and Medical Care of Texas, PLLC (together, the "PCs") were established to employ healthcare providers to deliver healthcare services to patients in New York, Tennessee and Texas. The Company concluded that it has variable interest in the PCs on the basis of its Administrative Service Agreements (the "ASAs") which provide for a management fee payable to the Company from the PCs in exchange for providing management and administrative services which creates risk and a potential return to the Company. The PCs' equity at risk, as defined by GAAP, is insufficient to finance their activities without additional support, and therefore, the PCs are considered to be VIEs.

In order to determine whether the Company has a controlling financial interest in the PCs, and, thus, is the PCs' primary beneficiary, the Company considered whether it has (i) the power to direct the activities of PCs that most significantly impacts their economic performance and (ii) the obligation to absorb losses of the PCs or the right to receive benefits from the PCs that could potentially be significant to them. The Company concluded that the member and employees of the PCs have no individual power to direct activities of the PCs that most significantly impact their economic performance. Under the ASAs, the Company is responsible for providing services that impact the growth of the patient population of the PCs, the management of that population's healthcare needs, the provision of required healthcare services to those patients, and the PCs' ability to receive revenue from health plans. In addition, the Company's variable interest in the PCs provides the Company with the right to receive benefits that could potentially be significant to them. The single member of the PCs is an employee of the Company. Based on this analysis, the Company concluded that it is the primary beneficiary of the PCs and therefore consolidates the balance sheet, results of operations and cash flow of the PCs.

Furthermore, as a direct result of nominal initial equity contributions by the single member of the PCs, the financial support CareMax provides to the PCs (e.g. loans) and the provisions of the arrangements described above, the interest held by the single member lacks economic substance and does not provide the member with the ability to participate in the residual profits or losses generated by the PCs. Therefore, all income and expenses recognized by the PCs are allocated to CareMax.

The following tables summarize the financial position and operations of the PCs (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30,<br>2022** | **December 31, 2021** |
| Total assets | $1215 | $- |
| Total liabilities | $2302 | $- |

---

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended September 30, 2022** | **Nine Months Ended<br>September 30, 2022** |
| Revenues | $22 | $22 |
| Operating expenses | $683 | $1064 |

---

**NOTE 15. SUBSEQUENT EVENTS**

In October 2022, in connection with the collaboration agreement with Elevance Health (formerly known as Anthem), which was announced in August 2021, the Company entered into a promissory note for an amount of $1.0 million due in October 2032. Funds received from Elevance Health pursuant to the aforementioned promissory note will be used to finance costs of one new center that will be opened in partnership with Elevance Health.

In November 2022, the Company drew $45.0 million of the Delayed Draw Terms Loans under the Credit Agreement. Refer to Note 6, Debt, for description of the terms of the Credit Agreement.

(20) ------

**Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

Unless the context otherwise requires, references in this section to "CareMax," "we," "us," "our," and the "Company" refers to CareMax, Inc. together with its consolidated subsidiaries. The following discussion and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity, capital resources and cash flows of our company as of and for the periods presented below. The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q/A (the "Report").

**Forward-Looking Statements**

This Report contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management. The words "anticipate," "believe," "plan," "expect," "may," "could," "should," "project," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement in not forward-looking. Actual results could differ materially from those discussed in these forward-looking statements due to a variety of risks and uncertainties and other factors, including, but not limited to those contained in our Annual Report on Form 10-K for the year ended December 31, 2021 (the "Annual Report"), which was filed with the Securities and Exchange Commission (the "SEC") on March 16, 2022, under the caption "Risk Factors," our subsequent quarterly reports and the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of the COVID-19 pandemic or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business, financial condition and results of operation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to grow and manage growth profitably, maintain relationships with customers, compete within its industry and retain our key employees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to integrate the businesses of CMG, IMC, SMA, DNF, Advantis and other acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to complete acquisitions and to open new centers and the timing of such acquisitions and openings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the viability of our growth strategy, including both organic and de novo growth and growth by acquisition, and our ability to realize expected results, as well as our ability to access the capital necessary for such growth;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to attract new patients;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the dependence of our revenue and operations on a limited number of key payors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the risk of termination, non-renewal or renegotiation of the Medicare Advantage ("MA") contracts held by the health plans with which we contract, or the termination, non-renewal or renegotiation of our contracts with those plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact on our business from changes in the payor mix of our patients and potential decreases in our reimbursement rates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to manage our growth effectively, execute our business plan, maintain high levels of service and patient satisfaction and adequately address competitive challenges;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of restrictions contained in certain of our agreements on our current and future operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•competition from primary care facilities and other healthcare services providers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•competition for physicians and nurses, and shortages of qualified personnel;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact on our business of reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program, including the MA program and other programs governing accountable care organizations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact on our business of state and federal efforts to reduce Medicaid spending;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•a shift in payor mix to Medicaid payors as well as an increase in the number of Medicaid patients may result in a reduction in the average rate of reimbursement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our assumption under most of our agreements with health plans of some or all of the risk that the cost of providing services will exceed our compensation;

(21) ------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•risks associated with estimating the amount of revenues and refund liabilities that we recognize under our risk agreements with health plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact on our business of security breaches, loss of data, or other disruptions causing the compromise of sensitive information or preventing us from accessing critical information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of our existing or future indebtedness and any associated debt covenants on our business and growth prospects;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact on our business of disruptions in our disaster recovery systems or management continuity planning;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the potential adverse impact of legal proceedings and litigation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of reductions in the quality ratings of the health plans we serve;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to maintain and enhance our reputation and brand recognition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to obtain, maintain and enforce intellectual property protection for our technology;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the potential adverse impact of claims by third parties that we are infringing on or otherwise violating their intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to protect the confidentiality of our trade secrets, know-how and other internally developed information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of any restrictions on our use of or ability to license data or our failure to license data and integrate third-party technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to protect data, including personal health data, and maintain our information technology systems from cybersecurity breaches and data leakage;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to adhere to all of the complex government laws and regulations that apply to our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our reliance on strategic relationships with third-parties to implement our growth strategy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact on our business if we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting U.S. healthcare reform;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•that estimates of market opportunity and forecasts of market and revenue growth included in this Quarterly Report may prove to be inaccurate, if at all;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our operating results and stock price may be volatile;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•risks associated with estimating the amount of revenues that we recognize under our risk agreements with health plans;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to navigate rules and regulations that govern our licensing and certification, as well as credentialing processes with private payors, before we can receive reimbursement for their services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to develop and maintain proper and effective internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Steward Transaction may not occur, and if it does, it may not be accretive and may cause dilution to our earnings per share, which may negatively affect the market price of our common stock.

Due to the uncertain nature of these factors, management cannot assess the impact of each factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Any forward-looking statement speaks only as of the date on which statement is made, and we undertake no obligation to update any of these statements or circumstances occurring after the date of this Report. New factors may emerge, and it is not possible to predict all factors that may affect our business and prospects.

(22) ------

**Our Business**

As of September 30, 2022, CareMax operated 51 centers in Florida, Tennessee, New York and Texas and planned to open 15 de novo centers during 2022, inclusive of the six opened during the nine months ended September 30, 2022. CareMax offers a comprehensive range of medical services, including primary and preventative care, specialist services, diagnostic testing, chronic disease management and dental and optometry services under global capitation contracts.

CareMax's centers offer 24/7 access to care through employed providers and provide a comprehensive suite of high-touch health care and social services to its patients, including primary care, specialty care, telemedicine, health & wellness, optometry, dental, pharmacy and transportation. CareMax's differentiated healthcare delivery model is focused on care coordination with vertically integrated ambulatory care and community-centric services. The goal of CareMax is to intercede as early as possible to manage chronic conditions for its patient members in a proactive, holistic, and tailored manner to provide a positive influence on patient outcomes and a reduction in overall healthcare costs. CareMax focuses on providing access to high quality care in underserved communities.

While CareMax's primary focus is providing care to Medicare eligible seniors who are mostly 65+ (approximately 80% of revenue for the nine months ended September 30, 2022 and 2021 came from these patients), we also provide services to children and adults through Medicaid programs as well as through commercial insurance plans. Substantially all of CareMax's Medicare patients are enrolled in MA plans which are run by private insurance companies and are approved by and under contract with Medicare. With MA, patients get all of the same coverage as original Medicare, including emergency care, and most plans also include prescription drug coverage. In many cases, MA plans offer more benefits than original Medicare, including dental, vision, hearing and wellness programs.

We believe we can translate the above premium services into economic benefits. By focusing on interventions that keep our patients healthy, we can capture the cost savings that our care model creates and reinvest them further in our care model. We believe these investments lead to better outcomes and improved patient experiences, which will drive further cost savings, power patient retention and enable us to attract new patients. We believe increasing cost savings over a growing patient population will deliver an even greater surplus to the organization, enabling us to reinvest to scale and fund new centers, progress our care model and enhance our technology.

**Pending Steward Transaction** 

In May 2022, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among (i) the Company, (ii) Sparta Merger Sub I Inc., a Delaware corporation and wholly-owned subsidiary of the Company, (iii) Sparta Merger Sub II Inc., a Delaware corporation and wholly-owned subsidiary of the Company, (iv) Sparta Merger Sub III Inc., a Delaware corporation and wholly-owned subsidiary of the Company, (v) Sparta Merger Sub I LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company, (vi) Sparta Merger Sub II LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company, (vii) Sparta Merger Sub III LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company, (viii) Sparta Sub Inc., a Delaware corporation ("SACN Holdco"), (ix) SNCN Holdco Inc. a Delaware corporation ("SNCN Holdco"), (x) SICN Holdco Inc., a Delaware corporation ("SICN Holdco" and, collectively with SACN Holdco, SNCN Holdco, Steward National Care Network, Inc., Steward Integrated Care Network, Inc., and Steward Accountable Care Network, Inc., each a "target" and, collectively, the "Targets"), (xi) Sparta Holding Co. LLC, a Delaware limited liability company (the "Seller"), and (xii) Steward Health Care System LLC, a Delaware limited liability company (referred to collectively with the Seller, the "Seller Parties"), pursuant to which the Company will acquire the Medicare value-based care business ("Steward Value-Based Care") of the Seller Parties (such transaction, the "Steward Transaction").

(23) ------

The aggregate consideration to be paid to the Seller at closing includes cash payment of $25 million, subject to customary adjustments, and 23,500,000 shares, subject to adjustment, of the Company's Class A common stock, $0.0001 par value per share ("Class A Common Stock"). In addition, the Merger Agreement provides for earnout share consideration that will be due to the Seller upon achievement of certain milestones. At closing, the Company will also issue to certain equityholders of the Seller shares of a newly designated series of preferred stock of the Company, which will provide voting rights to such Seller equityholders, until the earlier of (i) the two year anniversary of the closing of the Steward Transaction and (ii) the issuance of earnout share consideration on certain discrete matters where such Seller equityholders are permitted to vote the Company's securities in their discretion under the investor rights agreement to be entered into between such equityholders of the Seller and the Company. Finally, at closing, the Company will also pay the Seller an amount equal to the value of the Target's accounts receivable attributable to Medicare value-based payments for the period between January 1, 2021 and the closing, minus the amount of such payments payable to the affiliate physicians of the Targets (the "Financed Net Pre-Closing Medicare AR").

During the three and nine months ended September 30, 2022, we have recognized $0.5 million and $3.5 million, respectively, of acquisition costs related to the pending Steward Transaction. We will continue to incur acquisition costs, including $8 million in fees to a financial advisor, payment of $3 million of which is contingent upon closing of the Steward Transaction, and payment of $5 million of which is contingent upon payment of the earnout share consideration to the Seller Parties. We will reflect this $8 million fee in our financial statements during the period in which the Steward Transaction closes.

In November 2022, the Company drew $45.0 million of the Delayed Draw Terms Loans under the Credit Agreement. The proceeds from this borrowing will be used to fund a portion of the Steward Transaction. We expect to incur incremental debt to finance the Financed Net Pre-Closing Medicare AR in connection with closing of the Steward Transaction.

On November 2, 2022, the Company's stockholders approved the issuance of stock as partial consideration for the Steward Transaction for purposes of compliance with the rules of the Nasdaq Stock Market LLC. The Steward Transaction is expected to close promptly after the filing of this Quarterly Report on Form 10-Q.

**Key Factors Affecting Our Performance**

**Our Patients**

As discussed above, CareMax partners with MA, Medicaid, and commercial insurance plans. While CareMax currently services mostly MA patients, we also accept Medicare Fee-for-Service patients. The chart below shows a breakdown of our current membership on a pro forma basis. This pro forma view assumes the Business Combination with IMC occurred on January 1, 2020, and is based upon estimates which we believe are reasonable:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Patient Count as of\*** | **Sep 30, 2020** | **Dec 31, 2020** | **Mar 31, 2021** | **Jun 30, 2021** | **Sep 30, 2021** | **Dec 31, 2021** | **Mar 31, 2022** | **Jun 30, 2022** | **Sep 30, 2022** |
| Medicare | 16500 | 16500 | 16500 | 21500 | 26500 | 33500 | 34000 | 37000 | 39500 |
| Medicaid | 22500 | 21000 | 23000 | 23500 | 24500 | 28000 | 28500 | 29500 | 31500 |
| Commercial | 15000 | 14500 | 15000 | 17500 | 17500 | 21500 | 21500 | 21500 | 22000 |
| Total Count | 54000 | 52000 | 54500 | 62500 | 68500 | 83500 | 84000 | 88000 | 93000 |

---

\*Figures may not sum due to rounding

Because CareMax accepts multiple insurance types, it uses a Medicare-Equivalent Member ("MCREM") value in reviewing key factors of its performance. To determine the Medicare-Equivalent, CareMax calculates the amount of support typically received by one Medicare patient as equivalent to the level of support received by three Medicaid or Commercial patients. This is due to Medicare patients on average having significantly higher levels of chronic and acute conditions that need higher levels of care. Due to this dynamic, a 3:1 ratio is applied when normalizing membership statistics year over year. The breakdown of membership on a pro forma basis using MCREM is below:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **MCREM Count as of\*** | **Sep 30, 2020** | **Dec 31, 2020** | **Mar 31, 2021** | **Jun 30, 2021** | **Sep 30, 2021** | **Dec 31, 2021** | **Mar 31, 2022** | **Jun 20, 2022** | **Sep 30, 2022** |
| Medicare | 16500 | 16500 | 16500 | 21500 | 26500 | 33500 | 34000 | 37000 | 39500 |
| Medicaid | 7500 | 7000 | 7600 | 7900 | 8100 | 9400 | 9400 | 9900 | 10600 |
| Commercial | 5000 | 4900 | 5100 | 5900 | 5800 | 7200 | 7200 | 7100 | 7300 |
| Total MCREM | 29000 | 28400 | 29200 | 35300 | 40400 | 50100 | 50600 | 54000 | 57400 |

---

\*Figures may not sum due to rounding

**Medicare Advantage Patients**

(24) ------

As of September 30, 2022, CareMax had approximately 39,500 MA patients of which 83% were in value-based, or risk-based, contracts. This means CareMax has been selected as the patient's primary care provider and is financially responsible for all of the patient's medical costs. For these patients CareMax is attributed an agreed percentage of the premium the MA plan receives from the Centers for Medicare and Medicaid Services ("CMS") (typically a substantial majority of such premium given the risk assumed by CareMax). A reconciliation is performed periodically and if premiums exceed medical costs paid by the MA plan, CareMax receives payment from the MA plan. If medical costs paid by the MA plan exceed premiums, CareMax is responsible to reimburse the MA plan.

**Medicaid Patients**

As of September 30, 2022, CareMax had approximately 31,500 Medicaid patients of which approximately 95% were in value-based contracts. Using the MCREM metric, the level of support required to manage these Medicaid patients equates to that of approximately 10,600 Medicare patients. In Florida, most Medicaid recipients are enrolled in the Statewide Medicaid Managed Care program.

Similar to the risk it takes with Medicare, CareMax is attributed an agreed percentage of the premium the Medicaid plan receives (typically a substantial majority of such premium given the risk assumed by CareMax). A reconciliation is performed periodically and if premiums exceed medical costs paid by the Medicaid plan, CareMax receives payment from the Medicaid plan. If medical costs paid by the Medicaid plan exceed premiums, we are responsible to reimburse the Medicaid plan.

**Commercial Patients**

As of September 30, 2022, CareMax managed approximately 22,000 commercial patients of which approximately 26% were under value-based contracts that provided upside-only financial incentives for quality and utilization performance. Using the MCREM, the level of support required to manage these commercial patients equates to that of approximately 7,300 Medicare patients.

CareMax cares for a number of commercial patients (approximately 14% of CareMax's total patients) for whom it is reimbursed on a fee-for-service basis via their health plan in situations where it does not have a capitation relationship with that particular health plan.

CareMax fee for-service revenue, received directly from commercial plans, on a per patient basis is lower than its per patient revenue for at-risk patients based in part because its fee-for-service revenue covers only the primary care services that it directly provides to the patient, while the risk revenue is intended to compensate it for the services directly performed by it as well as the financial risk that it assumes related to the third-party medical expenses of at-risk patients.

**Contract with Payors**

Our economic model relies on its capitated partnerships with payors which manage and market MA plans across the United States. CareMax has established strategic value-based relationships with eleven different payors for Medicare Advantage patients, four different payors for Medicaid patients and one payor for Affordable Care Act ("ACA") patients. Our three largest payor relationships were Payor A, Payor B and Payor C, which generated 30%, 19% and 17% of our revenue, respectively, during the nine months ended September 30, 2022. During the nine months ended September 30, 2021 our largest payor relationships were Payor A, Payor D, and Payor E, which generated 46%, 17%, and 16% of our revenue on a pro forma basis, assuming the Business Combination with IMC occurred on January 1, 2021. These existing contracts and relationships with our partners' understanding of the value of the CareMax model reduces the risk of entering into new markets as CareMax typically has payor contracts before entering a new market. Maintaining, supporting, and growing these relationships, particularly as CareMax enters new markets, is critical to our long-term success. We believe CareMax's model is well-aligned with its payor partners - to drive better health outcomes for their patients, enhancing patient satisfaction, while driving incremental patient and revenue growth. This alignment of interests helps ensures our continued success with our payor partners.

**Effectively Manage the Cost of Care for Our Patients**

The capitated nature of our contracting with payors requires us to prudently manage the medical expense of our patients. Our external provider costs are our largest expense category, representing 65% of our total operating expenses for the nine months

(25) ------

ended September 30, 2022 and 65% of our total operating expenses for the nine months ended September 30, 2021. Our care model focuses on leveraging the primary care setting as a means of avoiding costly downstream healthcare costs, such as acute hospital admissions. Our patients retain the freedom to seek care at ERs or hospitals; we do not restrict their access to care. Therefore, we could be liable for potentially large medical claims should we not effectively manage our patients' health. We utilize stop-loss insurance for our patients, protecting us for medical claims per episode in excess of certain levels.

**Center-Level Contribution Margin**

We endeavor to expand our number of centers and number of patients at each center over time. Due to the significant fixed costs associated with operating and managing our centers, we generate significantly better center-level contribution margins as the patient base within our centers increases and our costs decrease as a percentage of revenue. As a result, the value of a center to our business increases over time when the number of patients at a center expands.

**Seasonality to our Business**

Due to the large number of dual-eligible patients (meaning eligible for both Medicare and Medicaid) we serve, the annual enrollment period does not materially affect our growth during the year. We typically see large increases in ACA patients during the first quarter as a result of the ACA annual enrollment period (October to December). However, this is not a large portion of our business.

Our operational and financial results will experience some variability depending upon the time of year in which they are measured. This variability is most notable in the following areas:

**Per-Patient Revenue**

The revenue derived from our at-risk patients is a function of the percentage of premium we have negotiated with our payor partners, as well as our ability to accurately and appropriately document the acuity of a patient. We experience some seasonality with respect to our per-patient revenue, as it will generally decline over the course of the year. In January of each year, CMS revises the risk adjustment factor for each patient based upon health conditions documented in the prior year, leading to changes in per-patient revenue. As the year progresses, our per-patient revenue declines as new patients join us, typically with less complete or accurate documentation (and therefore lower risk-adjustment scores), and patient mortality disproportionately impacts our higher-risk (and therefore greater revenue) patients.

**External Provider Costs**

External provider costs will vary seasonally depending on a number of factors, but most significantly the weather. Certain illnesses, such as the influenza virus, are far more prevalent during colder months of the year, which can result in an increase in medical expenses during these time periods. We would therefore expect to see higher levels of per-patient medical costs in the first and fourth quarters. Medical costs also depend upon the number of business days in a period. Shorter periods will have lesser medical costs due to fewer business days. Business days can also create year-over-year comparability issues if one year has a different number of business days compared to another. We would also expect to experience an impact in the future should there be another pandemic such as COVID-19, which may result in increased or decreased total medical costs depending upon the severity of the infection, the duration of the infection and the impact to the supply and availability of healthcare services for our patients.

**Investments in Growth**

We expect to continue to focus on long-term growth through investments in our centers, care model and marketing. In addition, we expect our corporate, general and administrative expenses to increase in absolute dollars for the foreseeable future to support our growth and additional costs as a public company, including expenses related to compliance with the rules and regulations of the SEC, Sarbanes-Oxley Act compliance, the stock exchange listing standards, additional corporate and director and officer insurance expenses, greater investor relations expenses and increased legal, audit and consulting fees. As we have communicated, we plan to invest in openings of new de novo centers over the next several years. Historically, de novo centers require upfront capital and operating expenditures, which may not be fully offset by additional revenues in the near-term, and we similarly expect a period of unprofitability in our future de novo centers before they break even. While our net income (loss) may decrease in the future because of these activities, we plan to balance these investments in future growth with a

(26) ------

continued focus on managing our results of operations and generating positive income from our core centers. In the longer term we anticipate that these investments will positively impact our business and results of operations.

**Key Business Metrics**

In addition to our financial information which conforms with generally accepted accounting principles in the United States of America ("GAAP"), management reviews a number of operating and financial metrics, including the following key metrics, to evaluate its business, measure its performance, identify trends affecting its business, formulate business plans, and make strategic decisions.

(27) ------

**Use of Non-GAAP Financial Information** 

Certain financial information and data contained in this Report is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any periodic filing, information or proxy statement, or prospectus or registration statement to be filed by the Company with the SEC. Some of the financial information and data contained in this Report, such as Adjusted EBITDA and Platform Contribution have not been prepared in accordance with GAAP. These non-GAAP measures of financial results are not GAAP measures of our financial results or liquidity and should not be considered as an alternative to net income (loss) as a measure of financial results, cash flows from operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. Management uses these non-GAAP measures for trend analyses and for budgeting and planning purposes.

The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends and in comparing the Company's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company's financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. For this reason, these non-GAAP measures may not be comparable to other companies' similarly labeled non-GAAP financial measures. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. You should review the Company's audited financial statements contained in the Annual Report.

**EBITDA and Adjusted EBITDA**

Management defines EBITDA as net income or net loss before interest expense, income tax benefit (expense), depreciation and amortization, change in fair value of derivative warrant liabilities, and gain or loss on extinguishment of debt. Adjusted EBITDA is defined as EBITDA adjusted for special items such as duplicative costs, non-recurring legal, consulting, and professional fees, stock-based compensation, de novo costs for the first 18 months after opening, discontinued operations, acquisition costs and other costs that are considered one-time in nature as determined by management. Additionally, Adjusted EBITDA presented on a pro forma basis gives effect to the acquisitions of IMC and Care Holdings Group, LLC ("Care Holdings"), which owned Care Optimize LLC, as if they had occurred in historical periods, which does not necessarily reflect what the Company's Adjusted EBITDA would have been had the acquisitions occurred on the dates indicated. Adjusted EBITDA is intended to be used as a supplemental measure of our performance that is neither required by, nor presented in accordance with, GAAP. Management believes that the use of Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing its financial measure with those of comparable companies, which may present similar non-GAAP financial measures to investors. However, we may incur future expenses similar to those excluded when calculating these measures. In addition, our presentations of these measures should not be construed as an inference that its future results will be unaffected by unusual or non-recurring items. Our computation of Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies may not calculate Adjusted EBITDA in the same fashion.

Due to these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on the GAAP results and using

(28) ------

Adjusted EBITDA on a supplemental basis. Please review the reconciliation of net income (loss) to EBITDA and Adjusted EBITDA below and do not rely on any single financial measure to evaluate the Company's business:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
| ($ in thousands) | **2022** | **2021** | **Y/Y Change** | **2022** | **2021** | **Y/Y Change** |
| Net income (loss) | $(22053) | $(14479) | $(7574) | $(48230) | $(3120) | $(45110) |
| &nbsp;&nbsp;GAAP Pro Forma adjustments (1) | - | - | - | - | (8917) | 8917 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pro Forma net income (loss) | (22053) | (14479) | (7574) | (48230) | (12037) | (36193) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 6076 | 1291 | 4785 | 11700 | 4358 | 7342 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 4573 | 5176 | (603) | 14538 | 11494 | 3044 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative warrant liabilities | 7331 | (10227) | 17558 | 3476 | (12022) | 15498 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on remeasurement of contingent earnout liabilities | - | 11625 | (11625) | - | (5794) | 5794 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on extinguishment of debt, net | - | (279) | 279 | 6172 | (1637) | 7809 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax provision | 181 | - | 181 | 532 | - | 532 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | (87) | 840 | (927) | 420 | 849 | (429) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EBITDA | (3978) | (6053) | 2075 | (11392) | (14791) | 3399 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other adjustments: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-recurring expenses (2) | 5940 | 4249 | 1691 | 15099 | 15302 | (203) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition costs (3) | 2118 | 1871 | 247 | 9621 | 6844 | 2777 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 3611 | 966 | 2645 | 7486 | 966 | 6520 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;De novo losses (4) | 1533 | 195 | 1338 | 3645 | 743 | 2902 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discontinued operations | - | - | - | - | (1) | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA | $9224 | $1229 | $7995 | $24460 | $9064 | $15396 |

---

Figures may not sum due to rounding.

(1) Pro Forma figures give effect to the Business Combinations of IMC and Care Holdings as if they had occurred in historical periods.

(2) Includes professional fees, salaries and wages, and other expenses deemed one-time in nature.

(3) Includes transaction costs, integration costs, and other costs to achieve synergies.

(4) Includes initial operating losses up to 18 months after center opening.

**Platform Contribution**

We define Platform Contribution as revenue less the sum of (i) external provider costs and (ii) cost of care. We believe this metric best reflects the economics of our care model as it includes all medical claims expense associated with our patients' care. As a center matures, we expect the Platform Contribution from that center to increase both in terms of absolute dollars as well as a percentage of capitated revenue. This increase will be driven by improving patient contribution economics over time, as well as our ability to generate operating leverage on the costs of our centers. Our aggregate Platform Contribution may not increase despite improving economics at our existing centers should we open new centers at a pace that skews our mix of centers towards newer centers. We would expect to experience minimal seasonality in Platform Contribution due to minimal seasonality in our patient contribution.

In addition to our GAAP financial information, we review a number of operating and financial metrics, including the following key metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. The chart below is a pro forma view of our operations. This pro forma view assumes the Business Combination occurred on January 1, 2020, and is based upon estimates which we believe are reasonable.

**Non-GAAP Operating Metrics**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Sep 30, 2020** | **Dec 31, 2020** | **Mar 31, 2021** | **Jun 30, 2021** | **Sep 30, 2021** | **Dec 31, 2021** | **Mar 31, 2022** | **Jun 30, 2022** | **Sep 30, 2022** |
| Centers | 22 | 24 | 24 | 34 | 40 | 45 | 48 | 48 | 51 |
| Markets | 1 | 1 | 1 | 2 | 3 | 4 | 6 | 6 | 7 |
| Patients (MCREM) | 29000 | 28400 | 29200 | 35300 | 40400 | 50100 | 50600 | 54000 | 57400 |
| At-risk | 85.6% | 87.7% | 87.0% | 84.1% | 87.2% | 79.3% | 79.8% | 81.0% | 78.2% |
| Platform Contribution ($, Millions) | $15.5 | $17.9 | $14.7 | $8.2 | $11.0 | $16.0 | $17.3 | $21.7 | $20.7 |

---

(29) ------

**Centers**

We define our centers as those primary care centers open for business and capable of attending to patients at the end of a particular period.

**Patients (MCREM)**

MCREM patients includes both at-risk MA patients (those patients for whom we are financially responsible for their total healthcare costs) as well as risk and non-risk, non-MA patients. We define our total at-risk patients as at-risk patients who have selected us as their provider of primary care medical services as of the end of a particular period. We define our total fee-for-service patients as fee-for-service patients who come to one of our centers for medical care at least once per year. A fee-for-service and at-risk patient remains active in our system until we are informed by the health plan the patient is no longer active. As discussed above, CareMax calculates the amount of support typically received by one Medicare patient as equivalent to the level of support received by three Medicaid or Commercial patients.

**Impact of COVID-19**

The rapid spread of COVID-19 around the world and throughout the United States altered the behavior of businesses and people, with significant negative effects on federal, state and local economies. The virus disproportionately impacts older adults, especially those with chronic illnesses, which describes many of our patients.

We estimate our performance for the nine months ended September 30, 2022 has been negatively impacted by approximately $1.0 million of direct COVID-19 costs, with negligible impact noted during the three months ended September 30, 2022.

Management cannot accurately predict the future impacts of COVID-19 due to the uncertainty surrounding future spikes in COVID-19 cases or new variants that may emerge in the future.

**Components of Results of Operations**

**Revenue**

Medicare risk-based revenue and Medicaid risk-based revenue. Our Medicare and Medicaid risk-based revenue consists primarily of capitation fees for medical services provided by us or managed by our MSO under a global capitation arrangement made directly with various MA payors. Capitation is a fixed amount of money per patient per month paid in advance for the delivery of health care services, whereby we are generally liable for medical costs in excess of the fixed payment and are able to retain any surplus created if medical costs are less than the fixed payment. A portion of our capitated revenues are typically prepaid monthly to us based on the number of MA patients selecting us as their primary care provider. Our capitated rates are determined as a percentage of the premium the MA plan receives from CMS for our at-risk members. Those premiums are determined via a competitive bidding process with CMS and are based upon the cost of care in a local market and the average utilization of services by the patients enrolled. Medicare pays capitation using a "risk adjustment model," which compensates providers based on the health status (acuity) of each individual patient. Payors with higher acuity patients receive more in premium, and those with lower acuity patients receive less in premium. Under the risk adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after the final data is compiled. As premiums are adjusted via this risk adjustment model, our capitation payments will change in unison with how our payor partners' premiums change with CMS. Risk adjustment in future periods may be impacted by COVID-19 and our inability to accurately document the health needs of our patients in a compliant manner, which may have an adverse impact on our revenue.

For Medicaid in Florida, premiums are determined by Florida's Agency for Health Care Administration ("AHCA") base rates and are adjusted annually using historical utilization data projected forward by a third-party actuarial firm. The rates are established based on specific cohorts by age and sex and geographical location. AHCA uses a "zero sum" risk adjustment model that establishes acuity for certain cohorts of patients quarterly, depending on the scoring of that acuity, and may periodically shift premiums from health plans with lower acuity members to health plans with higher acuity members.

(30) ------

Other revenue. Other revenue includes professional capitation payments. These revenues are a fixed amount of money per patient per month paid in advance for the delivery of primary care services only, whereby CareMax is not liable for medical costs in excess of the fixed payment. Capitated revenues are typically prepaid monthly to CareMax based on the number of patients selecting us as their primary care provider. Our capitated rates are fixed, contractual rates. Incentive payments for Healthcare Effectiveness Data and Information Set ("HEDIS") and any services paid on a fee for service basis by a health plan are also included in other revenue. Other revenue also includes ancillary fees earned under contracts with certain payors for the provision of certain care coordination and other care management services. These services are provided to patients covered by these payors regardless of whether those patients receive their care from our affiliated medical groups. Revenue for primary care service for patients in a partial risk or up-side only contract, pharmacy revenue and revenue generated from Care Holdings are reported in other revenue.

We expect capitated revenue will increase as a percentage of total revenues over time because of the greater revenue economics associated with at-risk patients compared to fee-for-service patients.

**Operating Expenses**

External provider costs. External provider costs include all services at-risk patients utilize. These include claims paid by the health plan and estimates for unpaid claims. The estimated reserve for incurred but not paid claims is included in accounts receivable as we do not directly pay medical claims. Actual claims expense will differ from the estimated liability due to factors in estimated and actual patient utilization of health care services, the amount of charges, and other factors. We typically reconcile our medical claims expense with our payor partners on a monthly basis and adjust our estimate of incurred but not paid claims if necessary. To the extent we revise our estimates of incurred but not paid claims for prior periods up or down, there would be a correspondingly favorable or unfavorable effect on our current period results that may or may not reflect changes in long term trends in our performance. We expect our medical claims expenses to increase in both absolute dollar terms as well as on a per patient per month ("PPPM") basis given the healthcare spending trends within the Medicare population and the increasing disease burden of patients as they age.

Cost of care. Cost of care includes the costs of additional medical services we provide to patients that are not paid by the plan. These services include patient transportation, medical supplies, auto insurance and other specialty costs, like dental or vision. In some instances, we have negotiated better rates than the health plans for these health plan covered services. In addition, cost of care includes payroll, rent and facilities costs required to maintain and operate our centers.

Expenses from our physician groups that contract with our MSO are consolidated with other clinical and MSO expenses to determine profitability for our at-risk and fee-for-service arrangements. Physician group economics are not evaluated on a stand-alone basis, as certain non-clinical expenses need to be consolidated to consider profitability.

We measure the incremental cost of our capitation agreements by starting with our center-level expenses, which are calculated based upon actual expenses incurred at a specific center for a given period of time and expenses that are incurred centrally and allocated to centers on a ratable basis. These expenses are allocated to our at-risk patients based upon the number of visit slots these patients utilized compared to the total slots utilized by all of our patients. All visits, however, are not identical and do not require the same level of effort and expense on our part. Certain types of visits are more time and resource intensive and therefore result in higher expenses for services provided internally. Generally, patients who are earlier in their tenure with CareMax utilize a higher percentage of these more intensive visits, as we get to know the patient and properly assess and document such patient's health condition.

Sales and marketing expenses. Sales and marketing expenses include the cost of our sales and community relations team, including salaries and commissions, radio and television advertising, events and promotional items.

Corporate, general and administrative expenses. Corporate, general and administrative expenses include employee-related expenses, including salaries and related costs and stock-based compensation, technology infrastructure, operations, clinical and quality support, finance, legal, human resources, and business development departments. In addition, corporate, general and administrative expenses include corporate technology, third party professional services and corporate occupancy costs. We expect these expenses to increase over time due to the additional legal, accounting, insurance, investor relations and other costs that we will incur as a public company, as well as other costs associated with continuing to grow our business. We also expect our corporate, general and administrative expenses to increase in absolute dollars in the foreseeable future. However, we anticipate corporate, general and administrative expenses to decrease as a percentage of revenue over the long term, although they may fluctuate as a percentage of revenue from period to period due to the timing and amount of these expenses.

(31) ------

Depreciation and amortization. Depreciation and amortization expenses are primarily attributable to our capital investments and consist of fixed asset depreciation, amortization of intangibles considered to have definite lives, and amortization of capitalized internal-use software costs.

Acquisition-related costs. Acquisition-related costs consist of legal and other transaction-related expenses.

**Nonoperating Income (Expenses)**

Interest expense. Interest expense consists primarily of interest payments on our outstanding borrowings.

Change in fair value of derivative warrant liabilities. Change in fair value of derivative warrant liabilities consists of changes in fair value of the Public Warrants and Private Placement Warrants.

Gain (loss) on remeasurement of contingent earnout liabilities. Gain (loss) on remeasurement of contingent earnout liabilities consists of changes in the fair value of contingent earnout liabilities.

Gain (loss) on extinguishment of debt. Gain (loss) on extinguishment of debt consists primarily of write-offs of unamortized debt issuance costs upon early repayments of debt.

Other income (expense), net. Other income (expense), net, consists of miscellaneous corporate expenses.

(32) ------

**Results of Operations**

**Three Months Ended September 30, 2022 compared to Three Months Ended September 30, 2021**

The following table sets forth our condensed consolidated statements of operations data for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** |  |  |
| ($ in thousands) | **2022** | **2021** | **$ Change** | **% Change** |
| **Revenue** |  |  |  |  |
| &nbsp;&nbsp;Medicare risk-based revenue | $122267 | $76428 | $45839 | 60.0% |
| &nbsp;&nbsp;Medicaid risk-based revenue | 19852 | 20884 | (1032) | (4.9%) |
| &nbsp;&nbsp;Other revenue | 15551 | 7308 | 8243 | 112.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 157670 | 104620 | 53050 | 50.7% |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;External provider costs | 106900 | 73329 | 33571 | 45.8% |
| &nbsp;&nbsp;Cost of care | 30213 | 21602 | 8611 | 39.9% |
| &nbsp;&nbsp;Sales and marketing | 2355 | 1274 | 1081 | 84.8% |
| &nbsp;&nbsp;Corporate, general and administrative | 21687 | 13589 | 8098 | 59.6% |
| &nbsp;&nbsp;Depreciation and amortization | 4573 | 5176 | (603) | (11.6%) |
| &nbsp;&nbsp;Acquisition related costs | 494 | 879 | (385) | (43.8%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total costs and expenses | 166222 | 115849 | 50373 | 43.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Operating income (loss)** | $(8552) | $(11229) | $2677 | (23.8%) |
| **Nonoperating income (expense)** |  |  |  |  |
| &nbsp;&nbsp;Interest expense | (6076) | (1291) | (4785) | 370.6% |
| &nbsp;&nbsp;Change in fair value of derivative warrant liabilities | (7331) | 10227 | (17558) | (171.7%) |
| &nbsp;&nbsp;Gain (loss) on remeasurement of contingent earnout liabilities | - | (11625) | 11625 | (100.0%) |
| &nbsp;&nbsp;Gain (loss) on extinguishment of debt | - | 279 | (279) | (100.0%) |
| &nbsp;&nbsp;Other income (expense), net | 87 | (840) | 927 | (110.3%) |
|  | (13320) | (3250) | (10070) | 309.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Income (loss) before income taxes** | $(21872) | $(14479) | $(7393) | 51.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax benefit (expense) | (181) | - | (181) | (100.0%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $(22053) | $(14479) | $(7574) | 52.3% |

---

\*Figures may not sum due to rounding

Medicare risk-based revenue. Medicare risk-based revenue was $122.3 million for the three months ended September 30, 2022, an increase of $45.8 million, or 60%, compared to $76.4 million for the three months ended September 30, 2021. This increase was driven primarily by a 51% increase in the total number of at-risk patients primarily from the acquisitions of CMG, SMA, DNF, and Advantis (the "Acquisitions") and the Business Combination with IMC and the conversion of partial risk patients to full risk, as well as a 6% increase in rates, driven by member mix.

Medicaid risk-based revenue. Medicaid risk-based revenue was $19.9 million for the three months ended September 30, 2022, a decrease of $1.0 million, or 5%, compared to $20.9 million for the three months ended September 30, 2021. This decrease was driven primarily by a 33% decrease in rates, driven by member mix, offset by a 26% increase in patients.

Other revenue. Other revenue was $15.6 million for the three months ended September 30, 2022, an increase of $8.2 million, or 113%, compared to $7.3 million for the three months ended September 30, 2021. The increase is related to fee-for-service and pharmacy revenues acquired in various acquisitions and higher HEDIS and other partial risk surplus payments.

External provider costs. External provider costs were $106.9 million for the three months ended September 30, 2022, an increase of $33.6 million, or 46%, compared to $73.3 million for the three months ended September 30, 2021. The increase was driven by incremental costs to support the 51% increase in revenue over the same period, which was driven by a 39% increase in at-risk patients, including Medicaid.

Cost of care expenses. Cost of care expenses were $30.2 million for the three months ended September 30, 2022, an increase of $8.6 million, or 40%, compared to $21.6 million for the three months ended September 30, 2021. The increase was due to increases in salaries and wages, medical supplies, and other related costs to support and operate the higher number of centers and members in the current period as a result of the impact of the Acquisitions and the Business Combination with IMC, as compared to the prior period.

Sales and marketing expenses. Sales and marketing expenses were $2.4 million for the three months ended September 30, 2022, an increase of $1.1 million, or 85%, compared to $1.3 million for the three months ended September 30, 2021. The increase

(33) ------

was primarily due to expanding our sales staff and marketing efforts to increase membership levels in our centers, as we have grown the number of centers we operate in 2022 as compared to 2021.

Corporate, general and administrative expenses. Corporate, general and administrative expenses were $21.7 million for the three months ended September 30, 2022, an increase of $8.1 million, or 60%, compared to $13.6 million for the three months ended September 30, 2021. The increase was primarily from higher salaries, wages and professional fees as we grow our corporate infrastructure to support our operational growth.

Depreciation and amortization. Depreciation and amortization expense was $4.6 million for the three months ended September 30, 2022, a decrease of $0.6 million, or 12%, compared to $5.2 million for the three months ended September 30, 2021. This decrease was primarily due to certain trademarks being fully amortized and certain fixed assets being fully depreciated throughout 2022.

Acquisition-related costs. Acquisition-related costs were $0.5 million for the three months ended September 30, 2022, a decrease of $0.4 million, or 44%, compared to $0.9 million during the three months ended September 30, 2021. In 2022, this cost relates primarily to the Steward Transaction.

Interest expense. Interest expense was $6.1 million for the three months ended September 30, 2022, an increase of $4.8 million, or 371%, compared to $1.3 million for the three months ended September 30, 2021. This current period increase was due to the increased borrowings and higher weighted-average interest rate. Refer to Note 6, Debt, for further information on the increased borrowing.

Change in fair value of derivative warrant liabilities. We recorded a loss of $7.3 million during the three months ended September 30, 2022, a decrease of $17.6 million, or 172%, compared to a gain of $10.2 million for the three months ended September 30, 2021. This decrease is primarily driven by the increase in CareMax's stock price during the three months ended September 30, 2022, as compared to the decrease in CareMax's stock price during the three months ended September 30, 2021.

Gain (loss) on remeasurement of contingent earnout liabilities. We recorded a loss on remeasurement of contingent earnout liabilities of $11.6 million during the three months ended September 30, 2021. Contingent earnout liabilities are no longer remeasured to fair value following their reclassification to equity during the third quarter 2021, accordingly, no gain or loss on contingent earnout liabilities was recognized in 2022.

Gain (loss) on extinguishment of debt. There were no extinguishments of debt during the three months ended September 30, 2022. During the three months ended September 30, 2021, we recorded a gain of $0.3 million related to the forgiveness of Payroll Protection Program ("PPP") loans.

Other income (expenses), net. Other income was $0.1 million for the three months ended September 30, 2022, an increase of $0.9 million as compared to other expenses of $0.8 million for the three months ended September 30, 2021.

(34) ------

**Nine Months Ended September 30, 2022 compared to Nine Months Ended September 30, 2021**

The following table sets forth our condensed consolidated statements of operations data for the periods indicated:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |  |  |
| ($ in thousands) | **2022** | **2021** | **$ Change** | **% Change** |
| **Revenue** |  |  |  |  |
| &nbsp;&nbsp;Medicare risk-based revenue | $373677 | $142005 | $231672 | 163.1% |
| &nbsp;&nbsp;Medicaid risk-based revenue | 59914 | 26333 | 33581 | 127.5% |
| &nbsp;&nbsp;Other revenue | 33278 | 9118 | 24160 | 265.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 466869 | 177456 | 289413 | 163.1% |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;External provider costs | 320104 | 127023 | 193081 | 152.0% |
| &nbsp;&nbsp;Cost of care | 87925 | 34822 | 53103 | 152.5% |
| &nbsp;&nbsp;Sales and marketing | 7955 | 2340 | 5615 | 239.9% |
| &nbsp;&nbsp;Corporate, general and administrative | 58728 | 24264 | 34464 | 142.0% |
| &nbsp;&nbsp;Depreciation and amortization | 14538 | 7127 | 7411 | 104.0% |
| &nbsp;&nbsp;Acquisition related costs | 3549 | 1028 | 2521 | 245.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 492799 | 196603 | 296196 | 150.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Operating income (loss)** | $(25930) | $(19147) | $(6783) | 35.4% |
| **Nonoperating income (expense)** |  |  |  |  |
| &nbsp;&nbsp;Interest expense | (11700) | (2587) | (9113) | 352.3% |
| &nbsp;&nbsp;Change in fair value of derivative warrant liabilities | (3476) | 12022 | (15498) | (128.9%) |
| &nbsp;&nbsp;Gain (loss) on remeasurement of contingent earnout liabilities | - | 5794 | (5794) | (100.0%) |
| &nbsp;&nbsp;Gain (loss) on extinguishment of debt | (6172) | 1637 | (7809) | (477.0%) |
| &nbsp;&nbsp;Other (expense) income, net | (420) | (840) | 420 | (50.0%) |
|  | (21768) | 16026 | (37794) | (235.8%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Income (loss) before income taxes** | $(47698) | $(3120) | $(44578) | 1428.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax benefit (expense) | (532) | - | (532) | (100.0%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $(48230) | $(3120) | $(45110) | 1445.8% |

---

Medicare risk-based revenue. Medicare risk-based revenue was $373.7 million for the nine months ended September 30, 2022, an increase of $231.7 million, or 163%, compared to $142.0 million for the nine months ended September 30, 2021. This increase was driven primarily by a 164% increase in the total number of at-risk patients from the Acquisitions and as a result of the Business Combination with IMC.

Medicaid risk-based revenue. Medicaid risk-based revenue was $59.9 million for the nine months ended September 30, 2022, an increase of $33.6 million, or 128% compared to $26.3 million for the nine months ended September 30, 2021. Medicaid risk-based revenue relates entirely to patients that were acquired from the Business Combination with IMC in June 2021.

Other revenue. Other revenue was $33.3 million for the nine months ended September 30, 2022, an increase of $24.2 million, or 265%, compared to $9.1 million for the nine months ended September 30, 2021. The increase is related to fee-for-service and pharmacy revenues from the Acquisitions and higher HEDIS and other surplus bonuses.

External provider costs. External provider costs were $320.1 million for the nine months ended September 30, 2022, an increase of $193.1 million, or 152%, compared to $127.0 million for the nine months ended September 30, 2021. The increase was driven by incremental costs to support the 163% increase in revenue over the same period, which was driven by a 159% increase in at-risk patients, including Medicaid, from the Acquisitions and as a result of the Business Combination with IMC, partially offset by a 3% decrease in rates, driven by member mix.

Cost of care expenses. Cost of care expenses were $87.9 million for the nine months ended September 30, 2022, an increase of $53.1 million, or 153%, compared to $34.8 million for the nine months ended September 30, 2021. The increase was due to increases in salaries and wages, medical supplies, and other related costs to support and operate the higher number of centers and members in 2022 as a result of the impact of the Acquisitions and the Business Combination with IMC, as compared to 2021.

Sales and marketing expenses. Sales and marketing expenses were $8.0 million for the nine months ended September 30, 2022, an increase of $5.6 million, or 240%, compared to $2.3 million for the nine months ended September 30, 2021. The increase was primarily higher salaries and wages and professional fees as we grow our corporate infrastructure to support our operational growth.

(35) ------

Corporate, general and administrative expenses. Corporate, general and administrative expenses were $58.7 million for the nine months ended September 30, 2022, an increase of $34.5 million, or 142%, compared to $24.3 million for the nine months ended September 30, 2021. The increase was primarily from the acquired overhead related to the Acquisitions and the Business Combination with IMC, as well as costs associated with becoming a publicly traded company.

Depreciation and amortization. Depreciation and amortization expense was $14.5 million for the nine months ended September 30, 2022, an increase of $7.4 million, or 104%, compared to $7.1 million for the nine months ended September 30, 2021. The increase is mostly driven by the higher amortization expense due to having nine months of amortization expense during the current period, as compared to approximately four months of amortization expense in the prior period, as we recorded intangible assets for the Business Combination with IMC in June 2021.

Acquisition-related costs. Acquisition-related costs were $3.5 million for the nine months ended September 30, 2022, an increase of $2.5 million, or 245%, compared to $1.0 million for the nine months ended September 30, 2021. This increase is primarily driven by the costs associated with the Steward Transaction.

Interest expense. Interest expense was $11.7 million for the nine months ended September 30, 2022, an increase of $9.1 million, or 352%, compared to $2.6 million for the nine months ended September 30, 2021. This increase was due to the increased borrowings and higher weighted-average interest rate. Refer to Note 6, Debt for further information on the increased borrowings.

Change in fair value of derivative warrant liabilities. We have recorded a loss of $3.5 million during the nine months ended September 30, 2022, a decrease of $15.5 million, or 129%, as compared to the gain of $12.0 million recognized during the nine months ended September 30, 2021. This decrease is driven primarily by the increase in interest rates. Refer to Note 9, Fair Value Measurements for further information on these warrants.

Gain (loss) on remeasurement of contingent earnout liabilities. We recorded a gain on remeasurement of contingent earnout liabilities of $5.8 million during the nine months ended September 30, 2021. Contingent earnout liabilities are no longer remeasured to fair value following their reclassification to equity during the third quarter 2021, accordingly, no gain or loss on contingent earnout liabilities was recognized in 2022.

Gain (loss) on extinguishment of debt. During the nine months ended September 30, 2022, in connection with the early extinguishment and termination of the Existing Credit Agreement, we have recognized a loss on extinguishment of debt of $6.2 million. During the nine months ended September 30, 2021, we recorded a gain of $1.6 million primarily driven by the forgiveness of PPP loans of $2.5 million, partially offset by a loss on extinguishment of debt of $0.8 million.

Other income (expenses), net. Other expenses were $0.4 million for the nine months ended September 30, 2022, a decrease of $0.4 million as compared to $0.8 million for the nine months ended September 30, 2021.

**Liquidity and Capital Resources**

**Overview**

As of September 30, 2022, we had cash on hand of $53.3 million. In addition, our Credit Agreement provides the ability to draw term loans in an amount up to $110 million under certain circumstances to finance permitted acquisitions and similar permitted investments, de novo center growth and optimization of de novo centers and management services organization performance. In November 2022, we borrowed $45.0 million of the Delayed Draw Term Loans under the Credit Agreement. The proceeds from this borrowing will be used to fund a portion of the Steward Transaction. We expect to incur incremental debt to finance the Financed Net Pre-Closing Medicare AR in connection with closing of the Steward Transaction.

Our principal sources of liquidity have been cash generated by our centers and MSO operations, borrowings under our credit facilities and proceeds from equity issuances. We have used these funds to meet our capital requirements, which consist of salaries, labor, benefits and other employee-related costs, product and supply costs, third-party customer service, billing and collections and logistics costs, capital expenditures including patient equipment, center and office lease expenses, insurance premiums, acquisitions and debt service. Our future capital expenditure requirements will depend on many factors, including the pace and scale of our expansion in new and existing markets, any future acquisitions, patient volume, and revenue growth rates. Many of our capital expenditures are made in advance of patients beginning service. Certain operating costs are incurred at the beginning of the equipment service period and during initial patient set up. We also expect to incur costs related to

(36) ------

acquisitions and de novo growth through the opening of new centers, which we expect to require significant capital expenditures, including lease and construction expenses. We may be required to seek additional equity or debt financing, in addition to cash on hand and borrowings under our Credit Facilities in connection with our business growth, including debt financing that may be available to us from certain health plans for each new center that we open under the terms of our agreements with those health plans. In the event that additional financing is required from outside sources, we may not be able to raise it on acceptable terms or at all. If additional capital is unavailable when desired, our business, results of operations, and financial condition would be materially and adversely affected. We believe that our existing cash, amounts available under our Credit Agreement, and amounts available to us under our agreement with Elevance Health, each as described below, will continue to be sufficient to fund our operations and growth strategies for at least the next 12 months.

**The Impact of COVID-19**

As further detailed above in "Impact of COVID-19", we estimate our performance during the nine months ended September 30, 2022, has been impacted by approximately $1.0 million of direct COVID-19 costs, with negligible impact noted during the three months ended September 30, 2022. While it is impossible to predict the scope or duration of COVID-19 or the future impact on our liquidity and capital resources, COVID-19 could materially affect our liquidity and operating cash flows in future periods.

**Credit Facilities**

In May 2022, the Company entered into the Credit Agreement that provided for an aggregate of up to $300 million in term loans, comprised of (i) initial term loans in aggregate principal amount of $190 million (the "Initial Term Loans") and (ii) a delayed term loan facility in the aggregate principal amount of $110 million (the "Delayed Draw Term Loans"). The Credit Agreement permits the Company to enter into certain incremental facilities subject to compliance with the terms, conditions and covenants set forth therein. In May 2022, the Company drew $190 million of the Initial Term Loans and used approximately $121 million of the net proceeds from this borrowing to repay its outstanding obligations under the credit agreement dated June 8, 2021, as amended (the "Existing Credit Agreement"). During the three and nine months ended September 30, 2022, the Company recognized debt extinguishment losses of $6.2 million related to early repayment of the Existing Credit Agreement.

Based on the elections made by the Company, as of September 30, 2022, the Initial Term Loan borrowings bear interest of Term SOFR (calculated as the Secured Overnight Financing Rate published on the Federal Reserve Bank of New York's website, plus a spread adjustment of 0.114%), plus an applicable margin rate of 9.00%. As permitted under the Credit Agreement, the Company elected to capitalize 4.00% of the interest as principal amount on the outstanding Term Loans. As a result of this election, the cash interest component of the applicable margin increases by 0.50%. Amortization payments under the Credit Agreement are payable in quarterly installments, commencing on March 31, 2024, in aggregate principal amounts equal to 0.25% of the outstanding principal balance. As of September 30, 2022, no amounts were borrowed under the Delayed Draw Term Loans and $190 million was outstanding under the Initial Term Loans. In November 2022, we borrowed $45.0 million of the Delayed Draw Term Loans under the Credit Agreement. All amounts owed under the Credit Agreement are due in May 2027.

The Credit Agreement contains certain covenants that limit, among other things, the ability of the Company and its subsidiaries to incur additional indebtedness, liens or encumbrances, to make certain investments, to enter into sale-leaseback transactions or sell certain assets, to make certain restricted payments or pay dividends, to enter into consolidations, to transact with affiliates and to amend certain agreements, subject in each case to the exceptions and other qualifications as provided in the Credit Agreement. The Credit Agreement also contains covenants that require the Company to satisfy a minimum liquidity requirement of $50.0 million, which may be decreased to $25.0 million if the Company achieves a certain adjusted EBITDA, and maintains a maximum total leverage ratio based on the Company's consolidated EBITDA, as defined in the Credit Agreement, with de novo losses excluded from the calculation of such ratio for up to 36 months after the opening of a de novo center, which maximum total leverage ratio will initially be 8.50 to 1.00, commencing with the fiscal quarter ended September 30, 2022 and is subject to a series of step-downs. For the fiscal quarters ending September 30, 2026 and thereafter, the Company must maintain a maximum total leverage ratio no greater than 5.50 to 1.00.

**Elevance Health Collaboration Agreement**

In connection with our collaboration agreement with Elevance Health (formerly known as Anthem), which was announced in August of 2021 (the "Elevance Collaboration Agreement"), we plan to open centers across eight priority states as part of our de novo strategy to open new centers in additional markets. Elevance Health has agreed to provide debt financing of up to $1

(37) ------

million for each new center opened in partnership with Elevance Health. We intend to use such funds to partially offset the costs of opening new centers in connection with our de novo growth strategy.

In October of 2022, in connection with the Elevance Collaboration Agreement we have entered into a promissory note for an amount of $1.0 million due in October 2032. Funds received from Elevance Health pursuant to the aforementioned promissory note will be used to finance costs of one new center that will be opened in partnership with Elevance Health.

**Cash Flows**

The following table summarizes our cash flows for the periods presented:

---

| | | |
|:---|:---|:---|
| (in thousands) | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2022** | **2021** |
| Net cash provided by (used in) operating activities | $(39811) | $(8801) |
| Net cash provided by (used in) investing activities | $(4969) | $(301311) |
| Net cash provided by (used in) financing activities | $50179 | $385630 |

---

Operating Activities. Net cash used in operating activities for the nine months ended September 30, 2022, was $39.8 million, an increase of $31.0 million, as compared to $8.8 million used in operating activities during the nine months ended September 30, 2021. This increase is primarily the result of an increase in accounts receivable of $47.4 million, offset by the effect of a $14.4 million increase in accounts payable and accrued expenses, both mostly driven by the timing of collections and payments and, to a lesser extent, the growth in total revenue.

Investing Activities. Net cash used in investing activities for the nine months ended September 30, 2022, was $4.9 million, which was driven by purchases of leasehold improvements and medical equipment for our centers, cash purchase consideration of $0.9 million related to the acquisition of two medical practices, offset by the return of funds held in escrow related to 2021 acquisitions, as compared to $301.3 million for the nine months ended September 30, 2021, primarily driven by the acquisitions of IMC and SMA.

Financing Activities. Net cash provided by financing activities for the nine months ended September 30, 2022, was $50.2 million driven by the proceeds of $184.0 million from borrowings issued under the Credit Agreement, offset by the early repayment of our Existing Credit Agreement and related debt issuance costs of $128.4 million. Net cash provided by financing activities of $385.6 million during the nine months ended September 30, 2021 was primarily related to the Business Combination, and consisted of $125.0 million of borrowings under the Existing Credit Agreement, $415.0 million from issuance and sale of Class A Common Stock, partially offset by cash used in the consummation of the reverse recapitalization of $108.4 million, repayment of borrowings of $26.1 million, equity issuance costs of $12.5 million, payment of deferred financing costs of $6.9 million and payment of debt prepayment penalties of $0.5 million.

**Contractual Obligations and Commitment**s

Our principal commitments consist of obligations under the Credit Agreement and operating leases for our centers.

**Off-Balance Sheet Arrangements**

We did not have any off-balance sheet arrangements as of September 30, 2022 or December 31, 2021, other than operating leases.

**JOBS Act**

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies, but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, as an emerging growth company, we can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our consolidated financial statements with a public company which is neither an emerging growth company, nor an emerging

(38) ------

growth company that has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

**Critical Accounting Policies and Estimates**

Other than addition of a policy related to accounting for VIEs, there have been no changes to our critical accounting policies and estimates as described in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 16, 2022.

**Variable Interest Entities**

The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity ("VIE"). These evaluations are complex, involve judgment, and the use of estimates and assumptions based on available historical information, among other factors. The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the VIE. The Company consolidates VIEs when it is determined that the Company is the primary beneficiary of the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company's involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively.

**Recent Accounting Pronouncements**

See Note 2 to our condensed consolidated financial statements "Summary of Significant Accounting Policies—Recent Accounting Pronouncements" included in this Report for more information.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

(39) ------

**Item 4. Controls and Procedures**

**Disclosure Controls and Procedures**

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of September 30, 2022. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls were not effective as of September 30, 2022, based on the material weaknesses identified below.

**Material Weaknesses in Internal Control over Financial Reporting**

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses we identified include that we lack a sufficient complement of professionals with the appropriate level of knowledge, training and experience to appropriately analyze, record and disclose accounting matters commensurate with our accounting and reporting requirements as a public company. This material weakness contributed to the Company not designing and maintaining formal controls to analyze, account for and disclose complex transactions, including the accounting for financial instruments and contingent earnout liabilities. These material weaknesses resulted in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the restatement of the Company's previously filed consolidated financial statements as of and for the year ended December 31, 2020, as well as the quarterly condensed consolidated financial information for the 2020 interim period ended September 30, 2020 related to derivative warrant liabilities, Class A ordinary shares subject to possible redemption, additional paid-in-capital, retained earnings/(deficit), fair value adjustment on derivative warrant liabilities, earnings per share and the related disclosures; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the restatement of the Company's previously filed quarterly condensed consolidated financial information for the 2021 interim periods ended June 30, 2021 and September 30, 2021 related to goodwill, contingent earnout liabilities, additional paid-in capital, retained earnings/(deficit), gain/(loss) on remeasurement of earnout liabilities, earnings per share and the related disclosures; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the restatement of the Company's previously filed consolidated financial statements as of and for the year ended December 31, 2021, as well as the quarterly condensed consolidated financial information for the 2021 interim period ended September 30, 2021 and the 2022 interim periods ended March 31, 2022, June 30, 2022, and September 30, 2022 related to warrants and prepaid expenses and other assets.

**Remediation Plan for the Material Weaknesses**

In response to the aforementioned material weaknesses, management has expended, and will continue to expend, a substantial amount of effort and resources for the remediation of material weaknesses in internal control over financial reporting. In 2021, management engaged an external advisor to assist in evaluating and documenting the design and operating effectiveness of our internal control over financial reporting, and their work is ongoing. Additionally, management has developed and started to execute a remediation plan, which included the hiring of a Vice President of Financial Reporting and Technical Accounting during the first quarter of 2022 and hiring of the Chief Accounting Officer with technical public company accounting and financial reporting experience during the third quarter of 2022. Our plan also includes providing enhanced access to accounting training, literature, research materials and documents and implementation of controls to review and evaluate conclusions regarding accounting for complex transactions. The material weaknesses will not be considered remediated until management completes the design and implementation of the measures described above and the controls operate for a sufficient period of time and management has concluded, through testing, that these controls are effective.

**Changes in Internal Control over Financial Reporting**

As described above, there were changes in our internal control over financial reporting during the three months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

(40) ------

**PART II. – OTHER INFORMATION**

**Item 1. Legal Proceedings**

From time to time, CareMax may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business. Although the results of litigation and claims are inherently unpredictable and uncertain, CareMax is not currently a party to any legal proceedings the outcome of which, if determined adversely to CareMax, are believed to, either individually or taken together, have a material adverse effect on CareMax's business, operating results, cash flows or financial condition. Regardless of the outcome, litigation has the potential to have an adverse impact on CareMax because of defense and settlement costs, diversion of management resources, and other factors.

**Item 1A. Risk Factors**

There have been no material changes from the Risk Factors except as disclosed in Part 1, Item 1A, of Amendment No. 2 to our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission on March 29, 2023.

**Risks Related to the Acquisition of the Medicare value-based care business of the Seller Parties**

**The Merger Agreement with the Seller Parties is subject to closing conditions and there can be no guarantee the Closing will occur.**

On May 31, 2022, we entered into the Merger Agreement with the Seller Parties and the other parties thereto. Pursuant to the Merger Agreement, among other consideration, we will issue at the Steward Closing 23,500,000 shares of Class A Common Stock (the "Initial Share Consideration"), and immediately following the Steward Closing, the equityholders of Seller are expected to own, in the aggregate, approximately 21% of the Company's Class A Common Stock. Additionally, following the Steward Closing, upon the Company's effective conversion of 100,000 Medicare patients from the Seller Parties' Medicare network to risk-based, value-based care arrangements with a Medical Expense Ratio of less than 85% for two consecutive calendar quarters, we will issue the Seller, for immediate distribution to its equityholders, a number of shares of Class A Common Stock (the "Earnout Share Consideration" and together with the Initial Share Consideration, the "Share Consideration") that, when added to the Initial Share Consideration, would have represented 41% of the issued and outstanding shares of Class A Common Stock as of the Steward Transaction Closing.

The Merger Agreement contains customary closing conditions set forth therein. There can be no guarantee that all conditions to the Steward Transaction Closing will be satisfied on a timely basis or at all. In the event that the Steward Transaction Closing does not occur, the anticipated benefits of the Steward Transactions will not be realized, which could have a material adverse effect on our future growth, business, financial condition and results of operations.

**The issuance of the Share Consideration will result in dilution to our stockholders and may adversely affect us, including the market price of our securities.**

The Initial Share Consideration to be issued under the Merger Agreement consists of 23,500,000 shares of Class A Common Stock, which is expected to be approximately 21% of the Company's Class A Common Stock issued and outstanding, will result in a significant, immediate dilution to the Company's stockholders and may cause the trading price of the Company's securities to decline. Additionally, upon the issuance of the Earnout Share Consideration, there will be significant additional dilution to the Company's stockholders, and even in the event that the Earnout Share Consideration is not issued, the potential for the issuance of the Earnout Share Consideration may negatively affect the trading price of the Company's securities in anticipation of such dilution. Additionally, the dilution caused by the Share Consideration could, among other things, limit the ability of our current stockholders to influence management of the Company post-closing.

Certain of the equityholders who will receive Share Consideration will be subject to lockup provisions that restrict the sale of the Class A Common Stock by such persons in excess of 4% of the total outstanding Class A Common Stock immediately following the Steward Transaction Closing for one year, subject to certain exceptions, but sales of a substantial number of the Equity Consideration Securities in the public market, or the perception that such sales may occur, could adversely affect the market price of our securities, notwithstanding such lockup provisions.

**Failure to complete the Steward Transaction could negatively impact the Company.**

(41) ------

If the Steward Transaction is not completed for any reason, there may be various adverse consequences and we may experience negative reactions from the financial markets and from our employees and patients. Additionally, if the Merger Agreement is terminated, the market price of our securities could decline to the extent that current market prices reflect a market assumption that the Steward Transaction will be beneficial and will be completed. We also could be subject to litigation related to any failure to complete the Steward Transaction or to perform our obligations under the Merger Agreement.

**The Acquisition may be more difficult, costly, or time-consuming than expected, and we may not realize the anticipated benefits of the Steward Transaction.**

To realize the anticipated benefits from the Steward Transaction, we must successfully integrate and combine our business with that of Steward Value-Based Care. If we are not able to successfully achieve these objectives, the anticipated benefits of the Steward Transaction may not be realized fully or at all or may take longer to realize than expected. In addition, the actual benefits of the Steward Transaction could be less than anticipated, and integration may result in additional unforeseen expenses. In addition, we and Steward Value-Based Care have operated and, until the completion of the Steward Transaction, must continue to operate, independently. It is possible that the integration process could result in the loss of one or more key employees, the disruption of each company's ongoing businesses or inconsistencies in standards, controls, procedures, and policies that adversely affect each company's ability to maintain relationships with doctors, patients, and employees or to achieve the anticipated benefits of the Steward Transaction. Integration efforts between the companies may also divert management attention and resources. These integration matters could have an adverse effect on CareMax during this transition period and for an undetermined period after completion of the Steward Transaction.

**We are subject to business uncertainties and contractual restrictions while the Steward Transaction is pending.**

Uncertainty about the effects of the Steward Transaction may have an adverse effect on us or Steward Value-Based Care. These uncertainties may impair Steward Value-Based Care's and our ability to attract, retain and motivate key personnel until the Steward Transaction is completed, and could cause third parties that deal with Steward Value-Based Care or us to seek to change existing business relationships, any of which could materially adversely impact our operations.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

None.

**Item 5. Other Information**

None.

**Item 6. Exhibits**

The following exhibits are filed as part of, or incorporated by reference into, this Report.

---

| | |
|:---|:---|
| **No.** | **Description of Exhibit** |
| [<u>31.1\*</u>](cmax-ex31_1.htm) | [<u>Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](cmax-ex31_1.htm) |
| [<u>31.2\*</u>](cmax-ex31_2.htm) | [<u>Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](cmax-ex31_2.htm) |
| [<u>32.1\*\*</u>](cmax-ex32_1.htm) | [<u>Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](cmax-ex32_1.htm) |
| [<u>32.2\*\*</u>](cmax-ex32_2.htm) | [<u>Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](cmax-ex32_2.htm) |
| 101.INS\* | Inline XBRL Instance Document |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document |

---

(42) ------

---

| | |
|:---|:---|
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | Inline XBRL Taxonomy Extension Labels Linkbase Document |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104\* | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\* Filed herewith.

\*\* Furnished herewith.

(43) ------

**SIGNATURES**

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CareMax Inc.**  | **CareMax Inc.**  |
| Date: March 29, 2023 |  | /s/ Carlos A. de Solo |
|  | Name:  | Carlos A. de Solo |
|  | Title: | President, Chief Executive Officer, and Director<br>(Principal Executive Officer) |
| Date: March 29, 2023 |  | /s/ Kevin Wirges |
|  | Name: | Kevin Wirges |
|  | Title: | Executive Vice President, Chief Financial Officer and Treasurer<br>(Principal Financial and Principal Accounting Officer) |

---

(44) ------

## Ex-31

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Carlos A. de Solo, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of CareMax, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 29, 2023

---

| |
|:---|
| /s/ Carlos A. de Solo |
| Name: Carlos A. de Solo |
| Title: President, Chief Executive Officer and Director |
| (Principal Executive Officer) |

---

------

## Ex-31

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Kevin Wirges, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of CareMax, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 29, 2023

---

| |
|:---|
| /s/ Kevin Wirges |
| Name: Kevin Wirges |
| Title: Executive Vice President, Chief Financial Officer and Treasurer  |
| (Principal Financial Officer) |

---

------

## Ex-32

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of CareMax, Inc. (the "Company") on Form 10-Q/A for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission (the "Report"), I, Carlos A. de Solo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Date: March 29, 2023

---

| |
|:---|
| /s/ Carlos A. de Solo |
| Name: Carlos A. de Solo |
| Title: President, Chief Executive Officer and Director |
| (Principal Executive Officer) |

---

------

## Ex-32

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of CareMax, Inc. (the "Company") on Form 10-Q/A for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission (the "Report"), I, Kevin Wirges, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

Date: March 29, 2023

---

| |
|:---|
| /s/ Kevin Wirges |
| Name: Kevin Wirges |
| Title: Executive Vice President, Chief Financial Officer and Treasurer |
| (Principal Financial Officer) |

---

------